{"version": "https://jsonfeed.org/version/1.1", "title": "Sharemaestro Newsreel: Sweden financial news", "home_page_url": "https://sharemaestro.com/newsreel/se/", "feed_url": "https://sharemaestro.com/newsreel/se/feed.json", "description": "Latest financial and company news from Sweden, newest first, with sector and industry sections and links to every source article.", "language": "en", "items": [{"id": "source:a98e42a382722bf2f7546d40e3bc97951c068ac0e511a17063075f75d48fa8ae", "url": "https://finance.yahoo.com/markets/stocks/articles/board-directors-truecaller-ab-proposes-105700744.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/board-directors-truecaller-ab-proposes-105700744.html", "title": "The Board of Directors of Truecaller AB proposes reduction of the share capital through cancellation of repurchased shares", "content_text": "STOCKHOLM, Aug. 14, 2026 /PRNewswire/ -- The Board of Directors of Truecaller AB (the \"Company\" or \"Truecaller\") has decided to propose a reduction of the share capital through cancellation of own B shares. The purpose of the proposal is to reduce the number of shares in own holdings in order to give the Company greater flexibility for share buy-back programs until the 2027 Annual General Meeting. At the 2026 Annual General Meeting, the Board of Directors was authorized to repurchase B shares until the 2027 Annual General Meeting. The authorization means that the Board of Directors may decide ", "date_published": "2026-08-14T10:57:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Capital return", "TRUE-B"], "_sharemaestro": {"country": "Sweden", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "TRUE-B", "name": "Truecaller AB (publ)", "sentiment_url": "https://sharemaestro.com/sentiment/9ab24db1-e883-4c0f-9d16-8dc640a6eb22/"}]}}, {"id": "source:1e1f1905b166e5b8d4f0f6670debc9605f79cc846abcc992a3f12da8984bcfe8", "url": "https://finance.yahoo.com/technology/articles/following-lg-samsungs-expansion-one-093500752.html", "external_url": "https://finance.yahoo.com/technology/articles/following-lg-samsungs-expansion-one-093500752.html", "title": "Following LG and Samsung's Expansion of All-in-One Ventless Heat Pump Dryers, New Study Projects 15.4% CAGR for Heat Pump Dryer Segment", "content_text": "Company Logo Accelerating urbanization, expanding residential infrastructure, and stringent energy efficiency regulations, highlighted by market leader Whirlpool Corporation's (>13.4% share) portfolio expansion, LG Electronics' and Samsung Electronics' rapid rollout of ventless heat pump technology, and European market strength across Electrolux AB, BSH Home Appliances Group, and Miele & Cie.\u2014are propelling the global cloth drying machine market from $21.7 billion in 2025 to a projected $41.6 billion by 2035, growing at a 6.8% CAGR. This 220-page study delivers a comprehensive evaluation acros", "date_published": "2026-08-14T09:35:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "ELUX-A"], "_sharemaestro": {"country": "Sweden", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ELUX-A", "name": "AB Electrolux (publ)", "sentiment_url": "https://sharemaestro.com/sentiment/335900a1-7298-4af6-8b26-7319e0e4512f/"}]}}, {"id": "source:e142f91199ddc701efe333aa5e8027026f2517e3c090202450a3265d89e820a2", "url": "https://finance.yahoo.com/markets/stocks/articles/bekaert-share-buyback-program-liquidity-061500238.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/bekaert-share-buyback-program-liquidity-061500238.html", "title": "Bekaert: Update on the Share Buyback Program and the Liquidity Agreement", "content_text": "Bekaert Update on the Share Buyback Program and the Liquidity Agreement Period from 6 August 2026 to 12 August 2026 Share Buyback Program On 26 February 2026, Bekaert announced the start of the next tranche of its share buyback program, for a total maximum consideration of up to \u20ac 75 million. As announced previously, the purpose of the Program is to cancel all shares repurchased. Bekaert announces today that during the period from 6 August 2026 to 12 August 2026, Kepler Cheuvreux SA on behalf of Bekaert has bought 56 000 shares. The table below provides an overview of the transactions under th", "date_published": "2026-08-14T06:15:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Capital return", "TIETOS"], "_sharemaestro": {"country": "Sweden", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "TIETOS", "name": "Tieto Oyj", "sentiment_url": "https://sharemaestro.com/sentiment/b5f80240-6b95-4861-8916-bb64fa5fe544/"}]}}, {"id": "source:628df1dfc51b43eaf5176f665aa8074ea9d077a0712fc5bd8d80d1a4d67c31c5", "url": "https://finance.yahoo.com/markets/stocks/articles/afarak-group-interim-report-h1-060000892.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/afarak-group-interim-report-h1-060000892.html", "title": "AFARAK GROUP: INTERIM REPORT H1 2026", "content_text": "Afarak Group SE 07:00 London, 09:00 Helsinki, 14 August 2026 - Afarak Group SE (\"Afarak\" or \"the Company\") (LSE: AFRK, NASDAQ: AFAGR) FINANCIAL INTERIM RELEASE H1 2026 H1/26 H1/25 2025 Revenue EUR million 57.1 77.1 141.3 EBITDA EUR million 1.6 6.9 -0.2 EBIT EUR million 0.5 5.9 -2.6 Earnings before taxes EUR million 0.1 3.4 -7.5 (Loss) / Profit for the period EUR million -0.7 2.4 -8.9 Earnings per share EUR 0.00 0.01 -0.03 EBITDA margin 2.8% 9.0% -0.2 EBIT margin 0.8% 7.7% -1.8 Earnings margin 0.2% 4.5% -5.3 Personnel (end of period) 625 613 626 FIRST HALF 2026 HIGHLIGHTS The Group recorded an ", "date_published": "2026-08-14T06:00:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "TIETOS"], "_sharemaestro": {"country": "Sweden", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "TIETOS", "name": "Tieto Oyj", "sentiment_url": "https://sharemaestro.com/sentiment/b5f80240-6b95-4861-8916-bb64fa5fe544/"}]}}, {"id": "source:0ada6890cb22d71f9eeaebf5baac970b5dab8f70dae2057cf86afa45eae8cb52", "url": "https://finance.yahoo.com/markets/stocks/articles/rottneros-ab-lts-0h0l-q2-010326334.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/rottneros-ab-lts-0h0l-q2-010326334.html", "title": "Rottneros AB (LTS:0H0L) (Q2 2026) Earnings Call Highlights: EBITDA Swings to Positive as Cost ...", "content_text": "This article first appeared on GuruFocus. EBITDA: SEK 31 million in Q2 2026, up from SEK -15 million in Q2 2025. Net Turnover (Rolling 12 Months): Approximately SEK 2.3 billion. Production Volume (Rolling 12 Months): 328,000 tons. NBSK Price: Down 9% in U.S. dollars year-over-year in Q2; dollar weakened by 3% in the same period. Wood Cost: Major cost improvement driver; accounted for 45% of cost structure in the first half of 2026. Fixed Costs: Reduced via savings program; personnel down to 266 from 288 a year ago. Investments: Expected to be approximately SEK 60 million this year versus SEK 1", "date_published": "2026-08-14T01:03:26+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "PEAB-B", "BURE", "NCC-A", "NCC-B"], "_sharemaestro": {"country": "Sweden", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "PEAB-B", "name": "Peab AB (publ)", "sentiment_url": "https://sharemaestro.com/sentiment/07d9869b-cf6a-4900-b797-9f45aab02d4b/"}, {"symbol": "BURE", "name": "Bure Equity AB (publ)", "sentiment_url": "https://sharemaestro.com/sentiment/02ca7714-1e2d-44b3-a4be-082a42c9442f/"}, {"symbol": "NCC-A", "name": "NCC AB (publ)", "sentiment_url": "https://sharemaestro.com/sentiment/0cfb6c1e-fd9f-48cc-a111-490dcfa36b3f/"}, {"symbol": "NCC-B", "name": "NCC AB (publ)", "sentiment_url": "https://sharemaestro.com/sentiment/cddef924-1cd5-4494-ae07-d8759816a49a/"}]}}, {"id": "source:9a1042d1042c0c4509f158d80dcf9539b676dda135ca2115c7cf499a5a21e8ca", "url": "https://finance.yahoo.com/technology/articles/volvo-trucks-60m-saved-ota-180638177.html", "external_url": "https://finance.yahoo.com/technology/articles/volvo-trucks-60m-saved-ota-180638177.html", "title": "Volvo Trucks: $60M Saved with OTA Updates [24% Fewer Stops]", "content_text": "Volvo Trucks is transforming fleet operations with groundbreaking over-the-air (OTA) software updates. Learn how this technology empowers drivers to initiate updates overnight or during breaks, eliminating downtime. Volvo's Chief Digital Officer Nicole Portello reveals how these updates have already cut unplanned stops by 24% and saved fleets an estimated $60 million in avoided downtime. Discover the impact of real-time data, predictive maintenance, and what's next for connected trucking. Volvo Trucks North America has driven its software update compliance rate from 25% to more than 80% of its", "date_published": "2026-08-13T18:06:38+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "VOLV-A", "VOLV-B"], "_sharemaestro": {"country": "Sweden", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "VOLV-A", "name": "AB Volvo (publ)", "sentiment_url": "https://sharemaestro.com/sentiment/fe8d0ecb-cf08-4cc7-bbe9-922c031ed18e/"}, {"symbol": "VOLV-B", "name": "AB Volvo (publ)", "sentiment_url": "https://sharemaestro.com/sentiment/f1d39f99-f2ad-497c-a0ad-50650ec0e904/"}]}}, {"id": "source:be47c71cd76c8d995f0f8acbc8432d526b99fa3350dca3b3eb608c067478f2b1", "url": "https://finance.yahoo.com/markets/stocks/articles/embracer-group-ab-thqqf-q1-150034329.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/embracer-group-ab-thqqf-q1-150034329.html", "title": "Embracer Group AB (THQQF) (Q1 2027) Earnings Call Highlights: Strong Organic Growth and ...", "content_text": "This article first appeared on GuruFocus. Net Sales: SEK3.9 billion, up 24% year over year, with 33% organic growth. Gross Margin: 56%, down 12 points year over year due to revenue mix. Cash EBIT: SEK47 million, up SEK146 million year over year. Free Cash Flow: Positive for the quarter, a significant improvement from minus SEK383 million in Q1 last year. Net Cash Position: SEK3.5 billion at quarter end, with total available funds of SEK6.4 billion. Fellowship Entertainment Net Sales: SEK810 million, a 22% organic decline. Fellowship Cash EBIT: SEK32 million, with a margin of minus 4%. Fellowsh", "date_published": "2026-08-13T15:00:34+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "EMBRAC-B"], "_sharemaestro": {"country": "Sweden", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "EMBRAC-B", "name": "Embracer Group AB (publ)", "sentiment_url": "https://sharemaestro.com/sentiment/641703ef-8386-40a7-b3b2-ee7a43af46b8/"}]}}, {"id": "source:0f7b4220286fc362c9f04460db69f7437d0af36fa9ec28860715b7310408eec4", "url": "https://finance.yahoo.com/technology/articles/skanska-signs-additional-contract-data-055200440.html", "external_url": "https://finance.yahoo.com/technology/articles/skanska-signs-additional-contract-data-055200440.html", "title": "Skanska signs an additional contract for a data center in Virginia, USA, worth USD 238M, about SEK 2.2 billion", "content_text": "STOCKHOLM, Aug. 13, 2026 /PRNewswire/ -- Skanska has signed an additional contract with an existing client to build a data center in Virginia, USA. The contract is worth USD 238M, about SEK 2.2 billion, which will be included in the US order bookings in the third quarter of 2026. The project includes the construction of a 22,000 square-meter (237,000-square-foot) data center, including five data halls, associated site work, and underground site utilities. This will be the second building constructed on the campus. Construction will start in August 2026 and will be completed in May 2028. For fu", "date_published": "2026-08-13T05:52:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Deals and strategy", "SKA-B"], "_sharemaestro": {"country": "Sweden", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "SKA-B", "name": "Skanska AB (publ)", "sentiment_url": "https://sharemaestro.com/sentiment/289f3196-db5c-46cd-b8a6-53c1f2a3089f/"}]}}, {"id": "source:a1a0ed9f4418b7f9a229661b8e7f83589e036c94201b2c2d26fac1714bf7a625", "url": "https://finance.yahoo.com/markets/stocks/articles/raute-oyj-ohel-raute-q2-011145560.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/raute-oyj-ohel-raute-q2-011145560.html", "title": "Raute Oyj (OHEL:RAUTE) (Q2 2026) Earnings Call Highlights: Strong Margins Amidst Weak Demand", "content_text": "This article first appeared on GuruFocus. Net Sales: EUR 33 million in Q2 2026, similar to Q1 2026 and lower than the year-ago period; first half net sales totaled EUR 66 million. Comparable EBITDA: EUR 4.0 million in Q2 2026, representing a 12% margin on net sales. Order Intake: EUR 18 million in Q2 2026, higher than a year ago but still at a low level; first half order intake was EUR 35 million. Earnings Per Share (EPS): EUR 0.36 in Q2 2026, down from the record-high level in the comparable period a year ago. Operating Cash Flow: Negative EUR 8 million in Q2 2026, the second consecutive quar", "date_published": "2026-08-13T01:11:45+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Macro sensitivity", "LUND-B", "NCC-A", "NCC-B"], "_sharemaestro": {"country": "Sweden", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "LUND-B", "name": "L E Lundbergf\u00f6retagen AB (publ)", "sentiment_url": "https://sharemaestro.com/sentiment/5b3c0533-d6d2-4aee-aaf9-468801d26add/"}, {"symbol": "NCC-A", "name": "NCC AB (publ)", "sentiment_url": "https://sharemaestro.com/sentiment/0cfb6c1e-fd9f-48cc-a111-490dcfa36b3f/"}, {"symbol": "NCC-B", "name": "NCC AB (publ)", "sentiment_url": "https://sharemaestro.com/sentiment/cddef924-1cd5-4494-ae07-d8759816a49a/"}]}}, {"id": "source:925017f4be8893e31a12586289c34f0c7ee514ff04b91b00d8b70dac2f840033", "url": "https://finance.yahoo.com/energy/articles/cez-xpra-cez-q2-2026-011013959.html", "external_url": "https://finance.yahoo.com/energy/articles/cez-xpra-cez-q2-2026-011013959.html", "title": "CEZ AS (XPRA:CEZ) (Q2 2026) Earnings Call Highlights: Net Income Rises 10% as Windfall Tax ...", "content_text": "This article first appeared on GuruFocus. Revenue: Operating revenue decreased 5% year-on-year, primarily due to lower power prices. EBITDA: Down 20% to CZK59 billion, impacted by lower generation prices and reduced trading profits. Net Income: Increased 10% to CZK18.1 billion, driven by the absence of the windfall profit tax, which ended on December 31, 2025. Operating Cash Flow: Increased by CZK26 billion, or 55% year-on-year. Capital Expenditures (CapEx): Increased 30% year-on-year. Net Debt: Approximately 9% higher, approaching CZK200 billion. Generation and Mining EBITDA: Decreased by CZK", "date_published": "2026-08-13T01:10:13+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "TIETOS"], "_sharemaestro": {"country": "Sweden", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "TIETOS", "name": "Tieto Oyj", "sentiment_url": "https://sharemaestro.com/sentiment/b5f80240-6b95-4861-8916-bb64fa5fe544/"}]}}, {"id": "source:75002d510a976d8fb1fd26d66ac0ca94ee02132e471459632ecb609c35c42bda", "url": "https://finance.yahoo.com/technology/ai/articles/gft-technologies-se-wbo-gft-010536877.html", "external_url": "https://finance.yahoo.com/technology/ai/articles/gft-technologies-se-wbo-gft-010536877.html", "title": "GFT Technologies SE (WBO:GFT) (H1 2026) Earnings Call Highlights: AI-Driven Growth and ...", "content_text": "This article first appeared on GuruFocus. Revenue: EUR462.6 million in H1 2026, a 5% increase in both euros and constant currencies. Adjusted EBIT: EUR33 million, up 8% year-over-year, with a margin of 7.1% compared to 6.8% in H1 2025. EBT: EUR24 million, up 26% year-over-year, with the EBT margin improving from 4.3% to 5.2%. Q2 Revenue: EUR233.04 million, a 6% increase versus Q2 2025. Q2 Adjusted EBIT: EUR16.5 million, a 10% increase versus Q2 2025. Order Backlog: Up 18% versus last year. Wynxx Soft Engineering Revenue: EUR24.4 million in actual influenced revenue in H1 2026. Wynxx Business P", "date_published": "2026-08-13T01:05:36+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "TIETOS"], "_sharemaestro": {"country": "Sweden", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "TIETOS", "name": "Tieto Oyj", "sentiment_url": "https://sharemaestro.com/sentiment/b5f80240-6b95-4861-8916-bb64fa5fe544/"}]}}, {"id": "source:89ccdae8021599987b6aa5f490674f932ae2eb912f9372cd9d18a81117ea95ac", "url": "https://finance.yahoo.com/real-estate/articles/nextensa-delivers-strong-half-results-155500459.html", "external_url": "https://finance.yahoo.com/real-estate/articles/nextensa-delivers-strong-half-results-155500459.html", "title": "Nextensa delivers strong half-year results, supported by several successful transactions", "content_text": "Nextensa NV PRESS RELEASE Regulated information Brussels, 12 August 2026, 5:55PM HIGHLIGHTS Nextensadeliversstronghalf-yearresults,supportedbyseveralsuccessful transactions Nextensa achieved strong results in the first half of 2026. The period was marked by several successful transactions, including the sale of Gewerbepark Stadlau in Vienna, the forward sale of The Rock and the sale of B&B Hotels in Cloche d'Or. The granting of the planning and environmental permits for Lake Side in Brussels and the reservation by Vicinity of a substantial residential portion of Bel Towers further underline th", "date_published": "2026-08-12T15:55:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "TELIA", "TIETOS"], "_sharemaestro": {"country": "Sweden", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "TELIA", "name": "Telia Company AB (publ)", "sentiment_url": "https://sharemaestro.com/sentiment/58a10a50-e778-4b19-94b0-8d2e612f8634/"}, {"symbol": "TIETOS", "name": "Tieto Oyj", "sentiment_url": "https://sharemaestro.com/sentiment/b5f80240-6b95-4861-8916-bb64fa5fe544/"}]}}, {"id": "source:d90e2209731c3b9a7749d90bee2a2e591fe83a02bb6808379f75ca9198499298", "url": "https://finance.yahoo.com/markets/world-indices/articles/european-equities-traded-us-american-151123119.html", "external_url": "https://finance.yahoo.com/markets/world-indices/articles/european-equities-traded-us-american-151123119.html", "title": "European Equities Traded in the US as American Depositary Receipts Edge Lower in Wednesday Trading", "content_text": "European equities traded in the US as American depositary receipts were edging lower late Wednesday PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in", "date_published": "2026-08-12T15:11:23+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "ERIC-A"], "_sharemaestro": {"country": "Sweden", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ERIC-A", "name": "Telefonaktiebolaget LM Ericsson (publ)", "sentiment_url": "https://sharemaestro.com/sentiment/55d58cf9-6ad7-46ac-b3d2-b3ac3eb4d992/"}]}}, {"id": "source:55dbed5d3c43d81c7484cc84af4c0ea094f5a4393865e303ba587743027088f7", "url": "https://finance.yahoo.com/markets/stocks/articles/pierre-vacances-center-parcs-total-133700984.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/pierre-vacances-center-parcs-total-133700984.html", "title": "Pierre & Vacances-Center Parcs: Total Number of Shares and Voting Rights", "content_text": "Pursuant to Article L. 233-8 of the French Commercial Code and Article 223-16 of the General Regulations of the French Autorit\u00e9 des march\u00e9s financiers PARIS, August 12, 2026--(BUSINESS WIRE)--Regulatory News: Pierre & Vacances-Center Parcs (Paris:VAC): Date Number of shares(*) Number of theoretical voting rights Number of actual voting rights (exercisable at General Meetings) (**) 31 July 2026 462 008 714 462 008 714 461 904 805 (*) Ordinary shares only, i.e. excluding 1,130 preferred shares not admitted to trading. (**) Excluding treasury shares, which are deprived of voting rights (the 1,130 preferred shares not carrying voting rights and are not being taken into account). PIERRE ET VACANCES Soci\u00e9t\u00e9 anonyme with a share capital 4,620,098,44 euros Si\u00e8ge social : L'Artois \u2013 11 rue de Cambrai \u2013 75947 Paris Cedex 19 316 580 869 R.C.S. Paris View source version on businesswire.com: https://www.businesswire.com/news/home/20260812714647/en/ Contacts Pierre & Vacances-Center Parcs View Comments", "date_published": "2026-08-12T13:37:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "TELIA"], "_sharemaestro": {"country": "Sweden", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "TELIA", "name": "Telia Company AB (publ)", "sentiment_url": "https://sharemaestro.com/sentiment/58a10a50-e778-4b19-94b0-8d2e612f8634/"}]}}, {"id": "source:fe5980e4b4672020bac139b9597c3b5776ed626cd5af89561eb3f3460a415d05", "url": "https://finance.yahoo.com/markets/stocks/articles/johan-westerlund-appointed-chief-transformation-120000954.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/johan-westerlund-appointed-chief-transformation-120000954.html", "title": "Johan Westerlund appointed Chief Transformation Officer of Martela Corporation and member of the Group Management Team", "content_text": "Martela Corporation Martela Corporation, Stock Exchange Release, 12.8.2026, at 15.00 Johan Westerlund (M.Sc. Econ.) has been appointed Chief Transformation Officer of Martela Corporation and member of Martela Corporation's Group Management Team. In his role, he will report to Panu Ala-Nikkola, CEO of the company. Westerlund will assume his position by the end of August 2026. Johan Westerlund has extensive experience in business management, leading demanding transformation and turnaround programmes, and renewing organisations in the Nordic countries. He also has a strong background in financial", "date_published": "2026-08-12T12:00:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "NCC-A", "NCC-B"], "_sharemaestro": {"country": "Sweden", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "NCC-A", "name": "NCC AB (publ)", "sentiment_url": "https://sharemaestro.com/sentiment/0cfb6c1e-fd9f-48cc-a111-490dcfa36b3f/"}, {"symbol": "NCC-B", "name": "NCC AB (publ)", "sentiment_url": "https://sharemaestro.com/sentiment/cddef924-1cd5-4494-ae07-d8759816a49a/"}]}}, {"id": "source:60b5609c387eb0bd080b0b77b3a5c1b730f5791d2fdf407bc0445aaa23ea6717", "url": "https://www.nasdaq.com/articles/which-financial-etf-better-buy-ishares-european-eufn-or-proshares-leveraged-uyg", "external_url": "https://www.nasdaq.com/articles/which-financial-etf-better-buy-ishares-european-eufn-or-proshares-leveraged-uyg", "title": "Which Financial ETF Is the Better Buy: iShares' European EUFN or ProShares' Leveraged UYG?", "content_text": "Key Points iShares MSCI Europe Financials ETF offers broad exposure to developed European markets at a lower cost than the leveraged ProShares alternative. ProShares - Ultra Financials uses 2x daily leverage, which creates significantly higher price volatility and resulted in a steeper maximum drawdown. While the ProShares fund provides a higher dividend yield, iShares MSCI Europe Financials ETF delivered a much higher 1-year total return of 31%.10 stocks we like better than iShares Trust - iShares Msci Europe Financials ETF \u203a iShares MSCI Europe Financials ETF(NASDAQ:EUFN) provides broad expo", "date_published": "2026-08-12T11:37:46+00:00", "authors": [{"name": "nasdaq.com"}], "tags": ["Capital return", "ALIV-SDB"], "_sharemaestro": {"country": "Sweden", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ALIV-SDB", "name": "Autoliv, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/88515181-cc9c-4adc-947d-aa131e4963af/"}]}}, {"id": "source:e36d474eb97ad2c336075d3dfe5a331dd95140d361056163840fbc0c12cb09bc", "url": "https://finance.yahoo.com/markets/stocks/articles/changes-full-guidance-biomar-113300186.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/changes-full-guidance-biomar-113300186.html", "title": "Changes to full-year guidance for BioMar", "content_text": "Aktieselskabet Schouw & Co. Today, BioMar has released an announcement with updated guidance for the full year 2026. BioMar now expects revenue in the range of DKK 17-18 billion against previously DKK 16-17 billion and EBIT in the range of DKK 1,200-1,300 million compared to previously DKK 1,100-1,200 million. BioMar constitutes a material part of the portfolio and is fully consolidated into the Schouw & Co. figures, and the information from BioMar will be incorporated into Schouw & Co.'s guidance. Schouw & Co. provides guidance to the market on revenue and EBITDA and will consider its consolidated full-year guidance based on the information from BioMar and the outlook for the other portfolio businesses no later than in connection with the release of the interim report scheduled on 14 August 2026. Aktieselskabet Schouw & Co. J\u00f8rgen Wisborg, Chairman of the Board of Directors Jens Bjerg S\u00f8rensen, President & CEO Please direct any questions to President Jens Bjerg S\u00f8rensen, telephone no. +45 86 11 22 22. Attachment 2026-08-12 FBM26-45 BioMar guidance ENG View Comments", "date_published": "2026-08-12T11:33:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "TELIA"], "_sharemaestro": {"country": "Sweden", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "TELIA", "name": "Telia Company AB (publ)", "sentiment_url": "https://sharemaestro.com/sentiment/58a10a50-e778-4b19-94b0-8d2e612f8634/"}]}}, {"id": "source:3f45a1751214ddc65e619a9736cac7c0685c9360585fcf20c878196e645dac16", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxPRW9Ec3Y3WEdPWF9lMG9Rc3VrQ1c0Tk1JYklESkl0STJ1c2JDTVZlUlYzRnExTDBjbEt0RXZpUURaNGVXS2E3NWtLWEVZdHBDbFdTR2t4Rm9rUmxYY01GSTA5dWpYcl9ETjRYUlVTRmJic3lfSURNdTJkRlhfUEd3V200LTQxRnVUeXltMlVaMi03WnNGRHctVGRuMlVKbmZocl8xSVRBdkVoRURu?oc=5", "external_url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxPRW9Ec3Y3WEdPWF9lMG9Rc3VrQ1c0Tk1JYklESkl0STJ1c2JDTVZlUlYzRnExTDBjbEt0RXZpUURaNGVXS2E3NWtLWEVZdHBDbFdTR2t4Rm9rUmxYY01GSTA5dWpYcl9ETjRYUlVTRmJic3lfSURNdTJkRlhfUEd3V200LTQxRnVUeXltMlVaMi03WnNGRHctVGRuMlVKbmZocl8xSVRBdkVoRURu?oc=5", "title": "Prisma Properties expands share buyback to 857,730 shares", "content_text": "Prisma Properties expands share buyback to 857,730 shares", "date_published": "2026-08-12T10:41:18+00:00", "authors": [{"name": "TipRanks"}], "tags": ["Capital return", "PRISMA"], "_sharemaestro": {"country": "Sweden", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "PRISMA", "name": "Prisma Properties AB (publ)", "sentiment_url": "https://sharemaestro.com/sentiment/11acebc2-782a-4de6-930b-5f7543af5197/"}]}}, {"id": "source:c9d7803c1ff374d637f6de96ed0d8f831c243aaef6fed16b2137d09e3ad94e60", "url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxPUjdGdDhCM212dm9RWG1aR2h2Y0U2dlNCX2UzaGVtOW9YZXNyM3Q4eWMxUTFzcnhLbkRHVWZQanJyOTRLZzFFOUtzX2dFTURWSTZqNDctUHUyY1lFWFk0cWRBczJPRkJyWWxuZkZYbHJnaWlvczVqdmd5NXN0Vi1jUHh1czYydGR3ZFNLb09Vb3pqT0hKNjAtaENhX0RQTXNDV0VzRk52b3RjYTIyR01OaEl4bU1nNFBRV1lUaExuSDFQZVJ3Nk9GcGR4MDlQa2s?oc=5", "external_url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxPUjdGdDhCM212dm9RWG1aR2h2Y0U2dlNCX2UzaGVtOW9YZXNyM3Q4eWMxUTFzcnhLbkRHVWZQanJyOTRLZzFFOUtzX2dFTURWSTZqNDctUHUyY1lFWFk0cWRBczJPRkJyWWxuZkZYbHJnaWlvczVqdmd5NXN0Vi1jUHh1czYydGR3ZFNLb09Vb3pqT0hKNjAtaENhX0RQTXNDV0VzRk52b3RjYTIyR01OaEl4bU1nNFBRV1lUaExuSDFQZVJ3Nk9GcGR4MDlQa2s?oc=5", "title": "Repurchase of own shares in Prisma Properties AB during week 32, 2026", "content_text": "Repurchase of own shares in Prisma Properties AB during week 32, 2026", "date_published": "2026-08-12T10:00:00+00:00", "authors": [{"name": "TradingView"}], "tags": ["Capital return", "PRISMA"], "_sharemaestro": {"country": "Sweden", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "PRISMA", "name": "Prisma Properties AB (publ)", "sentiment_url": "https://sharemaestro.com/sentiment/11acebc2-782a-4de6-930b-5f7543af5197/"}]}}, {"id": "source:bda2136f62bf5b8c21cac29df8d689788f9ded70a5d5d064ca5e3036d2daa14e", "url": "https://finance.yahoo.com/technology/ai/articles/tencent-eu-fund-invest-ai-093246165.html", "external_url": "https://finance.yahoo.com/technology/ai/articles/tencent-eu-fund-invest-ai-093246165.html", "title": "Tencent, EU Fund Invest in AI Coding Startup Lovable at $13 Billion Valuation", "content_text": "(Bloomberg) -- Swedish coding startup Lovable has raised funding at a $13.3 billion valuation, bringing in fresh capital to compete with larger rivals like Anthropic and Elon Musk's SpaceX. Most Read from Bloomberg Five Takeaways From Zuckerberg's 6,500-Word Manifesto on AI Phoebe Gates Knew Phia Shopping App Took Credit for Sales It Didn't Drive Pakistan Says Deal Is Close Even as Iran, US Harden Stances Tata Sons Chairman to Step Down, Deepening Leadership Turmoil Trump Weighs Call for Capital Gains Tax Cuts as Midterm Boost The Stockholm-based company said on Wednesday that it completed a $400 million Series C round led by Menlo Ventures and the Scaleup Europe Fund, a European Union investment vehicle run by EQT AB. Several venture capital firms also participated, along with new investors from Latin America and Asia, including Tencent Holdings Ltd. Formed in 2023, Lovable is one of the better known \"vibe-coding\" startups, which provides artificial intelligence tools letting people without programming knowhow build websites and apps. Coding automation has emerged as one of the few generative AI capabilities businesses are willing to spend on regularly. Anthropic's Claude Code, an AI coding assistant, has exploded in popularity, forcing rivals like OpenAI and Google to offer similar features. Musk's SpaceX agreed to buy Lovable's competitor Cursor for $60 billion in June to complement xAI's offerings. Cognition AI Inc., which makes an AI coding agent, is in discussions to raise funding at a valuation of $40 billion, Bloomberg News reported this week. Lovable has emphasized its adoption by corporate customers, which include Adidas AG, Deutsche Telekom AG and media firm Hearst. The startup previously raised money eight months ago, with $300 million in financing for a $6.6 billion valuation. Its new financing is one of the first disclosed investments from the EU's \u20ac5 billion ($5.8 billion) startup fund. Most Read from Bloomberg Businessweek Supercharged by Social Media, the GLP-1 Boom Is Warping Teen Psyches ICE Arrests Are Pushing Immigrant Families Deeper Into Poverty Lululemon Is At War With Itself With EV Sales Slowing, Hybrid Cars Are Hot Again Suno Says AI Is the Future of Music. Record Labels Say It's Theft \u00a92026 Bloomberg L.P. View Comments", "date_published": "2026-08-12T09:32:46+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "EQT"], "_sharemaestro": {"country": "Sweden", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "EQT", "name": "EQT AB (publ)", "sentiment_url": "https://sharemaestro.com/sentiment/5864ff09-5475-4f52-8efe-e3e66f9cbb91/"}]}}, {"id": "source:823f75b91e7b6b40c1d27a42d89fc7466f8107516ad56ea484a3a2544c23bdef", "url": "https://finance.yahoo.com/markets/stocks/articles/martela-corporations-half-report-1-050000284.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/martela-corporations-half-report-1-050000284.html", "title": "Martela Corporation's Half Year Report 1 January - 30 June 2026", "content_text": "Martela Corporation Martela Corporation, Half year report, 12.8.2026, at 08:00 a.m. The revenue and operating result for January-June 2026 weakened compared to the same period of the previous year. April\u2013June 2026 Revenue was EUR 14.5 million (24.6), representing a change of -41.0% Comparable operating result EUR -1.6 million Operating result was EUR -0.5 million (0.1) Operating profit per revenue was -3.3% (0.5%) The result for the period was EUR -1.0 million (-0.4) Earnings per share amounted to EUR -0.26 (-0.09) January\u2013June 2026 Revenue was EUR 32.0 million (50.2), representing a change of", "date_published": "2026-08-12T05:00:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "PEAB-B", "NCC-A", "NCC-B"], "_sharemaestro": {"country": "Sweden", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "PEAB-B", "name": "Peab AB (publ)", "sentiment_url": "https://sharemaestro.com/sentiment/07d9869b-cf6a-4900-b797-9f45aab02d4b/"}, {"symbol": "NCC-A", "name": "NCC AB (publ)", "sentiment_url": "https://sharemaestro.com/sentiment/0cfb6c1e-fd9f-48cc-a111-490dcfa36b3f/"}, {"symbol": "NCC-B", "name": "NCC AB (publ)", "sentiment_url": "https://sharemaestro.com/sentiment/cddef924-1cd5-4494-ae07-d8759816a49a/"}]}}, {"id": "source:02bdde7ef50a86b3878373f3e862a443c365b815016d87163ed20b42978c8b6b", "url": "https://finance.yahoo.com/markets/stocks/articles/martela-lowers-2026-revenue-result-044000965.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/martela-lowers-2026-revenue-result-044000965.html", "title": "Martela lowers its 2026 revenue and result guidance", "content_text": "Martela Corporation Martela Corporation, Inside Information, 12.8.2026 at 07:40 a.m. Due to market uncertainty and weak demand, Martela lowers its full-year revenue and result guidance. The company estimates that its revenue for 2026 will amount to approximately EUR 66\u201373 million and that its comparable operating result will be negative by EUR 1\u20133 million. New guidance for 2026: Martela Group's full-year revenue for 2026 is estimated to amount to approximately EUR 66\u201373 million. The comparable operating result is estimated to be negative by EUR 1\u20133 million. Previous guidance for 2026: Martela ", "date_published": "2026-08-12T04:40:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Macro sensitivity", "PEAB-B", "NCC-A", "NCC-B"], "_sharemaestro": {"country": "Sweden", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "PEAB-B", "name": "Peab AB (publ)", "sentiment_url": "https://sharemaestro.com/sentiment/07d9869b-cf6a-4900-b797-9f45aab02d4b/"}, {"symbol": "NCC-A", "name": "NCC AB (publ)", "sentiment_url": "https://sharemaestro.com/sentiment/0cfb6c1e-fd9f-48cc-a111-490dcfa36b3f/"}, {"symbol": "NCC-B", "name": "NCC AB (publ)", "sentiment_url": "https://sharemaestro.com/sentiment/cddef924-1cd5-4494-ae07-d8759816a49a/"}]}}, {"id": "source:dca284bb066b60bbf91f93101142188fab3d49b0b2476f9732ab4e090f4f98c0", "url": "https://finance.yahoo.com/healthcare/articles/astrazeneca-400bn-deal-unravelled-040028643.html", "external_url": "https://finance.yahoo.com/healthcare/articles/astrazeneca-400bn-deal-unravelled-040028643.html", "title": "How AstraZeneca\u2019s $400bn deal unravelled", "content_text": "One Broadway deal to start: Hollywood mogul Ari Emanuel has struck a roughly \u00a34.5bn deal to buy the theatre group behind West End venues including the Lyceum and the Savoy in a major bet that strong demand for live events is here to stay. In today's newsletter: AstraZeneca's Silver Upgrade to read this Financial Times article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade now", "date_published": "2026-08-12T04:00:28+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "AZN"], "_sharemaestro": {"country": "Sweden", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "AZN", "name": "AstraZeneca PLC", "sentiment_url": "https://sharemaestro.com/sentiment/9a46cc60-2cd4-4018-a7c4-8318e07d9155/"}]}}, {"id": "source:71a851c14fd85444c47c17893916ebe1b0fe76ccc4bc8e8a0c6e38fcf0f08afb", "url": "https://finance.yahoo.com/markets/stocks/articles/technotrans-se-wbo-ttr1-q2-010228002.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/technotrans-se-wbo-ttr1-q2-010228002.html", "title": "technotrans SE (WBO:TTR1) (Q2 2026) Earnings Call Highlights: Margin Resilience and Strategic ...", "content_text": "This article first appeared on GuruFocus. Revenue: EUR113.3 million in H1 2026, down 6% from EUR120.6 million in the prior year. EBIT: EUR8.0 million in H1 2026, compared to EUR8.4 million one year ago. EBIT Margin: Increased to 7.1% from 7.0% in the prior year. Gross Profit: EUR34.2 million, with gross margin improving to 30.2% from 29.8%. EBITDA: EUR11.2 million, compared to EUR11.9 million in the previous year; EBITDA margin rose to 9.9% from 9.8%. Net Profit: EUR4.9 million, down from EUR5.2 million in the prior year. Earnings Per Share: EUR0.71, compared to EUR0.75 in the previous year. Free Cash Flow: EUR0.5 million in H1 2026, down from EUR1.1 million in the prior year; positive at EUR0.9 million in Q2. Order Backlog: EUR96 million at the end of June, up 14% from the end of March. Book-to-Bill Ratio: 1.2, with order intake exceeding revenue by 20%. Technology Segment Revenue: EUR84 million, down from EUR90.8 million; segment EBIT margin improved to 4.4% from 4.3%. Services Segment Revenue: EUR29.4 million, close to the prior year's EUR29.8 million; EBIT margin remained high at 14.7%. Energy Management and Laser Revenue: Approximately EUR32 million, up 8% year-over-year; excluding laser, growth was 17%. Healthcare and Analytics Revenue: Approximately EUR17 million, up 6% year-over-year. Print Revenue: EUR36 million, down approximately 10% year-over-year. Plastics Revenue: Approximately EUR26 million, down 19% year-over-year. Equity Ratio: Solid at 63.6%. Net Debt: EUR14.5 million, up from EUR8.3 million at the end of 2025; net debt to EBITDA ratio at 0.62. Warning! GuruFocus has detected 7 Warning Signs with JSEJF. Is WBO:TTR1 fairly valued? Test your thesis with our free DCF calculator. Release Date: August 04, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points EBIT margin improved to 7.1% despite a 6% revenue decline, marking the seventh consecutive quarter of stable margins around 7%. Order backlog surged 14% to EUR96 million, with a book-to-bill ratio of 1.2, indicating strong future revenue visibility. Energy Management division grew 17% (excluding laser), driven by robust demand in data center liquid cooling and battery thermal management. Secured a major long-term plastics order with recurring revenue of over EUR10 million annually, plus several large cooling plant orders. Healthcare & Analytics revenue rose 6%, supported by a new liquid cooling system for CT scanners with orders exceeding expectations in Asia. Story Continues Negative Points Group revenue fell 6% to EUR113.3 million, primarily due to continued weakness in Print and Plastics markets. Plastics division suffered a 19% revenue decline, reflecting weak economic conditions and prolonged market downturn. Supply chain restrictions for heat exchangers, pumps, and compressors pose a risk to production and could impact second-half performance. Free cash flow turned positive only in Q2, with first-half cash flow at EUR0.5 million, impacted by working capital buildup. Management expects full-year revenue to likely land in the lower half of the EUR240-260 million guidance range due to ongoing market volatility. Q & A Highlights Q: Given the strong order intake, is it fair to assume the 2027 growth rate will exceed the H2 2026 growth rate?A: Michael Finger (CEO): Yes. The strategic wins, including the significant jump in plastics revenue which will be fully in place next year, will make a difference. Assuming market conditions stay stable and other markets perform as they have this year, we see a nice growth rate in 2027. Q: Can you shed light on which of the larger orders are reflected in the Q2 order backlog and which come on top? Will Q3 also see a positive book-to-bill ratio?A: Michael Finger (CEO): The EUR96 million order backlog reflects only the first half. The major plastics order announced last week is not included and comes on top. Regarding Q3, one month is done and we see a posit", "date_published": "2026-08-12T01:02:28+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "TELIA"], "_sharemaestro": {"country": "Sweden", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "TELIA", "name": "Telia Company AB (publ)", "sentiment_url": "https://sharemaestro.com/sentiment/58a10a50-e778-4b19-94b0-8d2e612f8634/"}]}}, {"id": "source:1fd6285db09f4b26802dc27a154122008a10fb893f54b18ab4c496cb879b1742", "url": "https://finance.yahoo.com/markets/stocks/articles/asmodee-group-ab-fra-2ex-010204696.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/asmodee-group-ab-fra-2ex-010204696.html", "title": "Asmodee Group AB (FRA:2EX) (Q1 2027) Earnings Call Highlights: Net Sales Surge 20. ...", "content_text": "This article first appeared on GuruFocus. Net Sales: EUR 422.1 million, up 20.9% (20.2% organically). Adjusted EBITDA: EUR 61.9 million, up 55%. Adjusted EBITDA Margin: 14.7%, up 330 basis points from 11.4% last year. Board Game Sales Growth: Up 16%. Trading Card Game Sales Growth: Up 23%. Free Cash Flow: EUR 37.5 million, compared with EUR 24.7 million in the same period last year. Net Debt to Adjusted EBITDA: 1.6 times before M&A commitments and 1.7 times after M&A commitments. Cash and Cash Equivalents: EUR 196.5 million at quarter end. Warning! GuruFocus has detected 5 Warning Sign with FR", "date_published": "2026-08-12T01:02:04+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Balance sheet", "ASMDEE-B"], "_sharemaestro": {"country": "Sweden", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ASMDEE-B", "name": "Asmodee Group AB (publ)", "sentiment_url": "https://sharemaestro.com/sentiment/1832ff21-8c11-499e-a7d9-5fc29a91f9c5/"}]}}, {"id": "source:ea7e7c83c69cf0488590973f55b3e45a00e458be651cdf2ada60e1789a419701", "url": "https://finance.yahoo.com/technology/articles/sbo-strengthens-position-3d-metal-211539467.html", "external_url": "https://finance.yahoo.com/technology/articles/sbo-strengthens-position-3d-metal-211539467.html", "title": "SBO Strengthens Position in 3D Metal Printing: Expanded Capacity in the US and the UK, Award for 3T", "content_text": "TERNITZ, AUSTRIA - August 11, 2026 (NEWMEDIAWIRE) - SBO AG, listed on the leading index ATX of the Vienna Stock Exchange, is expanding its 3D metal printing capacity in the US and the UK and strengthening its market position in Europe through an award for its subsidiary 3T. Both steps advance SBO's diversification strategy in the growing additive manufacturing market. In the US, SBO has expanded additive manufacturing capacity by adding one VELO XC and two Renishaw 500Q printers for high-performance alloys Inconel and Titanium in Q2 2026. In addition, two more VELO XC printers have been ordered and will be delivered and operational in Q3 2026. In parallel, SBO expands the additive manufacturing space at its Houston, Texas site by 50% to more than 2,100 m. This additional capacity in conjunction with the existing excellence in high-precision post-processing serves rising customer demand from the space, aerospace, defense, semiconductor, energy and other industries. This positions SBO well for the strong growth of the additive manufacturing market from roughly USD 1.5 bn in 2025 to USD 4.8 bn by 2030. SBO is also strengthening its market position in 3D metal printing in Europe. 3T Additive Manufacturing Limited, based in Newbury, UK, has been part of SBO's Precision Technology division since October 2025 and recently received market recognition: at the Thames Valley Tech & Innovation Awards 2026, 3T was named \"Tech SME of the Year\". The jury recognized the team's technical expertise, its leadership in material and process data, and its continued growth in metal additive manufacturing. In addition, 3T has also expanded its printing capacity by adding another M400 to its fleet of EOS printers in Q2 2026. In Q3 2026, a second printer has also been ordered and will be delivered by the end of the quarter. 3T has also invested further in post-processing equipment. With the acquisition of 3T, SBO expands its customer base in the high-growth industries of space, aerospace, defense and semiconductors. Klaus Mader, CEO of SBO, says: \"3D metal printing is a key pillar of our diversification strategy, through which we are broadening our business beyond the oil and gas industry and continuing our transformation into a high-precision technology group. It is an attractive growth market: 3D metal printing is growing significantly faster than our core business and is gaining further momentum. We are capitalizing on that dynamic. We leverage our core capabilities in high-performance materials and high-precision manufacturing, offering the entire value chain from a single source, from printing to post-processing. With the new printers and expanded manufacturing space in the US and the award-winning performance of 3T in Europe, we are expanding where demand is highest: in space, aerospace, defense and semiconductors.\" About SBO SBO AG is leading in the manufacture of high-alloy, non-magnetic steels, high-precision components and high-tech equipment for the energy sector and other industrial sectors. The global high-precision technology group, headquartered in Ternitz, Austria, operates worldwide at more than 20 locations with around 1,500 employees. The group delivers cutting-edge technologies backed by a highly innovative product portfolio and strong intellectual property. In its Precision Technology division, SBO specializes in high-precision metal components, ranging from complex steel parts to additive manufacturing solutions for industries requiring maximum accuracy and performance. In the Energy Equipment division, SBO provides high-tech equipment for directional drilling and well completion including high-precision flow control products. Designed for extreme conditions, these solutions perform in high-temperature and high-pressure environments, serving important industries including oil and gas, energy and other industrial sectors. SBO is listed in the leading index ATX of the Vienna Stock Exchange (ISIN AT0000946652). More information: www.", "date_published": "2026-08-11T21:15:39+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "BILL"], "_sharemaestro": {"country": "Sweden", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "BILL", "name": "Billerud AB (publ)", "sentiment_url": "https://sharemaestro.com/sentiment/ae46ec7f-2011-4bd8-870f-0d21b34f48f4/"}]}}, {"id": "source:d020dcec0b98dd69fca8599c593931e0a64b09972ed300339d8883d457300d3f", "url": "https://finance.yahoo.com/markets/stocks/articles/nokia-declines-28-7-three-155100838.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/nokia-declines-28-7-three-155100838.html", "title": "Nokia Declines 28.7% in Three Months: Should You Buy the Dip?", "content_text": "Nokia Corporation NOK shares have declined 28.7% in the past three months compared with the industry's decline of 9.3%. The stock has underperformed the Zacks Computer & Technology sector and the S&P 500 during the same time frame.Zacks Investment Research Image Source: Zacks Investment Research The company has underperformed its peers like Arista Networks, Inc. ANET and Ericsson ERIC. Shares of Ericsson have declined 18.2%, and shares of Arista have risen 34.6%. Nokia Plagued by Stiff Competition, Weakness in the Legacy Business Nokia operates in highly competitive telecommunications equipment markets. In this market, pricing, technology differentiation and customer procurement decisions influence contract awards and long-term profitability. Ericsson, with its robust portfolio strength, remains a major rival. The company is also facing strong competition from Arista in the growing AI networking market as well. Although Nokia continues to strengthen its AI-native networking portfolio and expand relationships with hyperscale cloud providers, competitors are pursuing similar opportunities across 5G, AI infrastructure and future 6G deployments. Maintaining technology leadership while preserving pricing discipline remains essential as customers balance network modernization against capital spending constraints. Nokia recorded \u20ac390 million of restructuring and associated charges in the second quarter of 2026. It is to be noted that Nokia now expects \u20ac800 million of restructuring charges in 2026 and \u20ac700-800 million of restructuring-related cash outflows. This also includes \u20ac350 million of China integration charges and another \u20ac200 million from additional restructuring, primarily in Europe. The restructuring should improve efficiency in the long run; this remains a major drag for near-term profitability. In the Mobile Infrastructure business, Nokia sales increased 7% year over year, but gross margin declined 70 basis points year over year to 49.3%, while operating margin declined 60 basis points to 11.6%. Mobile Infrastructure remains a major revenue earner for the company. Declining profitability, despite growing revenues, is a major concern. Nokia Benefits From Strength in AI Infrastructure, Portfolio Strength Nokia continues to benefit from its broad portfolio spanning mobile networks, optical transport, IP routing, fixed broadband, software and services. This integrated offering enables the company to address evolving customer requirements across telecommunications operators, enterprises and hyperscale cloud providers. Nokia owns approximately 20,000 patents, including around 7,000 patents essential to 5G technologies. Its 5G portfolio continues to gain traction among enterprise customers, supporting recurring opportunities beyond traditional carrier spending cycles. Network Infrastructure delivered double-digit growth in second-quarter 2026, supported by continued momentum in Optical Networks and IP Networks. Optical Networks business grew 20% year over year in the second quarter, supported by AI & Cloud demand, as well as telecom investment. Nokia is also investing heavily in optical manufacturing capacity, including expanding advanced testing and packaging capacity in Pennsylvania. The company is also developing additional U.S. semiconductor manufacturing capabilities. Management also increased its expectation for full-year Network Infrastructure sales growth to 12-14%, reflecting continued demand for advanced networking solutions. Growing investment in AI infrastructure is becoming a more important long-term growth driver for Nokia. During second-quarter 2026, AI and Cloud revenues more than doubled year over year while order intake reached EUR 2.8 billion. Management noted that approximately half of these long-term orders are expected to convert into revenue over the next 12 months. Story Continues Estimate Revision Trend The company's earnings estimates for 2026 have declined, and 2027 have improved over the past 60 days.Z", "date_published": "2026-08-11T15:51:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "ERIC-A", "ERIC-B"], "_sharemaestro": {"country": "Sweden", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ERIC-A", "name": "Telefonaktiebolaget LM Ericsson (publ)", "sentiment_url": "https://sharemaestro.com/sentiment/55d58cf9-6ad7-46ac-b3d2-b3ac3eb4d992/"}, {"symbol": "ERIC-B", "name": "Telefonaktiebolaget LM Ericsson (publ)", "sentiment_url": "https://sharemaestro.com/sentiment/ef94dea1-4ffa-4fd3-b67c-cfec302a2322/"}]}}, {"id": "source:9aa46f143d12e6836ec8f87a34db6d65cf855cbdd55b1193f49cfedc1ca6926e", "url": "https://finance.yahoo.com/markets/stocks/articles/h-h-international-interim-financial-151800335.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/h-h-international-interim-financial-151800335.html", "title": "H+H International A/S: Interim Financial Report, H1 2026", "content_text": "Company announcement No. 10/2026 CHIEF EXECUTIVE OFFICER J\u00d6RG BRINKMANN QUOTE COPENHAGEN, Denmark, Aug. 11, 2026 /PRNewswire/ -- \"Following the severe winter weather in Q1, we delivered the expected normalization in Q2 and improved EBIT before special items to DKK 43 million. While market conditions remain challenging, particularly in the UK, we continue to see the expected benefits from our German restructuring programme and therefore maintain our full-year outlook.\" PERFORMANCE HIGHLIGHTS FOR Q2 2026 (Q2 2025) Revenue growth measured in local currencies (\"organic growth\") was 6% (0%). Sales ", "date_published": "2026-08-11T15:18:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "LUND-B", "PEAB-B", "BURE", "NCC-A", "NCC-B"], "_sharemaestro": {"country": "Sweden", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "LUND-B", "name": "L E Lundbergf\u00f6retagen AB (publ)", "sentiment_url": "https://sharemaestro.com/sentiment/5b3c0533-d6d2-4aee-aaf9-468801d26add/"}, {"symbol": "PEAB-B", "name": "Peab AB (publ)", "sentiment_url": "https://sharemaestro.com/sentiment/07d9869b-cf6a-4900-b797-9f45aab02d4b/"}, {"symbol": "BURE", "name": "Bure Equity AB (publ)", "sentiment_url": "https://sharemaestro.com/sentiment/02ca7714-1e2d-44b3-a4be-082a42c9442f/"}, {"symbol": "NCC-A", "name": "NCC AB (publ)", "sentiment_url": "https://sharemaestro.com/sentiment/0cfb6c1e-fd9f-48cc-a111-490dcfa36b3f/"}, {"symbol": "NCC-B", "name": "NCC AB (publ)", "sentiment_url": "https://sharemaestro.com/sentiment/cddef924-1cd5-4494-ae07-d8759816a49a/"}]}}, {"id": "source:e5c992282af748582727e0b379a28e826a56314aefe9cf6970cf79b0179e0274", "url": "https://finance.yahoo.com/markets/stocks/articles/storskogen-group-ab-stu-0vk-150028207.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/storskogen-group-ab-stu-0vk-150028207.html", "title": "Storskogen Group AB (STU:0VK) (Q2 2026) Earnings Call Highlights: Organic Growth Accelerates to ...", "content_text": "This article first appeared on GuruFocus. Net Sales: SEK 8.86 billion, up 5% year-over-year, driven by organic growth. Adjusted EBITDA: SEK 1.13 billion, up 2% year-over-year. Adjusted EBIT: SEK 864 million, up 2% year-over-year. Adjusted EBITDA Margin: 9.7%, compared with 10% in Q2 2025; essentially unchanged year-over-year when adjusted for a one-off effect. Adjusted Operating Profit (EBIT): SEK 693 million, up 3% year-over-year. Net Profit After Tax: SEK 413 million, up 18% year-over-year. Adjusted Earnings Per Share: SEK 0.23, up 23% year-over-year. Cash Flow from Operating Activities: SEK", "date_published": "2026-08-11T15:00:28+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "STOR-B"], "_sharemaestro": {"country": "Sweden", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "STOR-B", "name": "Storskogen Group AB (publ)", "sentiment_url": "https://sharemaestro.com/sentiment/f76243c2-b9d7-475f-a3a3-03d3047fd391/"}]}}, {"id": "source:307c68c8377bcf013ad783581ce907b734df56f45e0558685346ed0bf0510ade", "url": "https://finance.yahoo.com/healthcare/articles/regn-soars-21-9-month-143000494.html", "external_url": "https://finance.yahoo.com/healthcare/articles/regn-soars-21-9-month-143000494.html", "title": "REGN Soars 21.9% in a Month: Buy, Sell or Hold the Stock?", "content_text": "The going has been strong for Regeneron Pharmaceuticals REGN over the past month. Shares of this biotech giant have surged 21.9% over the said time frame, outpacing the industry's growth of 4%. The stock has also outperformed the sector and the S&P 500 Index during this time. REGN's robust rally has been driven by better-than-expected quarterly results, which can be attributed to robust demand for Eylea HD (higher dose of Eylea) and higher profit-sharing from Dupixent that helped the company mitigate the decline in Eylea sales. REGN Outperforms Industry, Sector and S&P 500 IndexZacks Investmen", "date_published": "2026-08-11T14:30:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "TIETOS"], "_sharemaestro": {"country": "Sweden", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "TIETOS", "name": "Tieto Oyj", "sentiment_url": "https://sharemaestro.com/sentiment/b5f80240-6b95-4861-8916-bb64fa5fe544/"}]}}, {"id": "source:b51a9c0acb44843e99204d8fb453958beffc103c488dbbba819b3ed9a4d2d207", "url": "https://finance.yahoo.com/markets/options/articles/options-traders-know-something-astrazeneca-141100595.html", "external_url": "https://finance.yahoo.com/markets/options/articles/options-traders-know-something-astrazeneca-141100595.html", "title": "Do Options Traders Know Something About AstraZeneca Stock We Don't?", "content_text": "Investors in AstraZeneca PLC AZN need to pay close attention to the stock based on moves in the options market lately. That is because the Jan. 15, 2027 $115.00 Call had some of the highest implied volatility of all equity options today. What is Implied Volatility? Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that may cause a big rally or a huge sell-off. However, implied volatility is only one piece of the puzzle when putting together an options trading strategy. What do the Analysts Think? Clearly, options traders are pricing in a big move for AstraZeneca shares, but what is the fundamental picture for the company? Currently, AstraZeneca is a Zacks Rank #4 (Sell) in the Medical - Biomedical and Genetics industry that ranks in the Bottom 38% of our Zacks Industry Rank. Over the last 60 days, no analysts have increased their earnings estimates for the current quarter, while one analyst has revised the estimate downward. The net effect has taken our Zacks Consensus Estimate for the current quarter from $2.75 per share to $2.64 in that period. Given the way analysts feel about AstraZeneca right now, this huge implied volatility could mean there's a trade developing. Oftentimes, options traders look for options with high levels of implied volatility to sell premium. This is a strategy many seasoned traders use because it captures decay. At expiration, the hope for these traders is that the underlying stock does not move as much as originally expected. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AstraZeneca PLC (AZN) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research View Comments", "date_published": "2026-08-11T14:11:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "AZN"], "_sharemaestro": {"country": "Sweden", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "AZN", "name": "AstraZeneca PLC", "sentiment_url": "https://sharemaestro.com/sentiment/9a46cc60-2cd4-4018-a7c4-8318e07d9155/"}]}}, {"id": "source:157f29885eab9b04cf8a5a81af1300536ff187ac011a500c0ee253bb620d6e35", "url": "https://finance.yahoo.com/healthcare/articles/hedge-funds-bullish-astrazeneca-plc-140427321.html", "external_url": "https://finance.yahoo.com/healthcare/articles/hedge-funds-bullish-astrazeneca-plc-140427321.html", "title": "Hedge Funds are Bullish on AstraZeneca PLC (AZN)", "content_text": "AstraZeneca PLC (NYSE:AZN) topped second-quarter profit expectations, with core earnings per share of $2.63 versus the $2.48 analysts expected. The firm reiterated its target of $80 billion in annual revenue by 2030. However, the quarter also brought fresh pipeline trouble: its rare disease drug Ultomiris missed its main goal in a late-stage trial for a rare blood vessel complication in adults, the latest in a string of setbacks that also includes an earlier heart drug trial failure and a breast cancer drug application that U.S. regulators rejected. Why One Trial Miss Shook Confidence in the Whole Pipeline AstraZeneca has built one of the richest valuations in European pharma on the assumption that its management reliably delivers successful late-stage trials. That assumption took a hit earlier this month when its heart drug Wainua failed a pivotal trial, sending shares down as much as 9% intraday before closing down 6.2%, the stock's worst single day in more than two years, followed by another 3% drop the next day. Most analysts say the actual sales impact from Wainua's failure is small, in the range of 2% to 4% of AstraZeneca PLC (NYSE:AZN)'s valuation, but the market reaction was roughly double that. It shows investors are questioning the broader pipeline, not just one drug. Even with the earnings beat, AstraZeneca's stock is still down for the year. This makes you question: is AstraZeneca's run-of-trial disappointments a temporary rough patch or a sign its premium valuation is no longer justified?Hedge Funds are Bullish on AstraZeneca PLC (AZN) The Bull Case The core business is genuinely strong. Oncology revenue rose 15% with cancer drugs Tagrisso and Imfinzi leading the way, and an experimental gastric cancer drug, sonesitatug vedotin, met its main survival goal in a late-stage trial. AstraZeneca PLC (NYSE:AZN) also won EU approval for its breast cancer drug camizestrant, which it sells as Etcamah, and is more than halfway through a plan to launch 20 new medicines by 2030. CEO Pascal Soriot said, \"I have never been more confident in the strength of our pipeline,\" and most analysts, including Citi and Bank of America, still recommend buying the stock. The Bear Case The pipeline disappointments are piling up. A U.S. regulatory panel rejected camizestrant on trial design grounds back in May, even as the EU approved it. Revenue from China, AstraZeneca's second biggest market, fell 13% due to generic competition and policy changes. AstraZeneca PLC (NYSE:AZN) is also adjusting its U.S. drug pricing in response to the Trump administration's most favored nation policy, which ties some U.S. prices to what other wealthy countries pay, a shift that could pressure margins in its most lucrative market. Investor attention now turns to a lung cancer trial called AVANZAR, which analysts have flagged as the next major catalyst likely to determine whether the stock's slump continues. Story Continues Insider Monkey's Hedge Fund Data Insider Monkey's hedge fund database shows AstraZeneca had 56 hedge fund holders as of Q1 2026, up from 52 the quarter before. The dollar value hedge funds held rose from about $4.21 billion to $5.50 billion. Among pharma peers, Sanofi had 32 holders, flat from the quarter before; Novartis had 31, down from 35, and GSK had just 31, down sharply from 43. AstraZeneca PLC (NYSE:AZN) draws more hedge fund interest than all three. Conclusion AstraZeneca's underlying business is still growing exactly as promised, but its recent run of trial failures means it now has less room for error. The market is judging every future readout more harshly than it used to. Overall, hedge funds are bullish on AstraZeneca PLC (NYSE:AZN). While we acknowledge the potential of AZN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see o", "date_published": "2026-08-11T14:04:27+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "AZN"], "_sharemaestro": {"country": "Sweden", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "AZN", "name": "AstraZeneca PLC", "sentiment_url": "https://sharemaestro.com/sentiment/9a46cc60-2cd4-4018-a7c4-8318e07d9155/"}]}}, {"id": "source:8dc753318c40bcc1666bbc6fb48d58022a30d0148989be9442b7bb88150302e2", "url": "https://finance.yahoo.com/markets/stocks/articles/mrk-stock-5-6-month-134800162.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/mrk-stock-5-6-month-134800162.html", "title": "MRK Stock Up 5.6% in a Month as Estimates Fall: Buy, Hold or Sell?", "content_text": "Merck's MRK stock is up 5.6% in a month. The key reason for the increase was the strong second-quarter 2026 performance. Merck beat estimates for both earnings and sales in the second quarter. Revenues in the second quarter increased 5% to $16.61 billion as higher sales of oncology drugs, including Keytruda, and contributions from new products like Winrevair, Welireg, and Capvaxive, and the Animal Health segment were partially offset by lower sales of Gardasil and some other vaccines. Sales of blockbuster PD-L1 inhibitor Keytruda increased 4% to $8.4 billion. Merck also raised its 2026 revenue outlook while lowering its adjusted EPS guidance to include costs related to the Terns acquisition. However, the higher costs have led to a significant decline in estimates. A scenario of rising stock price but declining estimates can confuse an investor about whether to buy, sell, or hold a stock. To make an investment decision, it is important to weigh the company's key strengths against the risks that could influence its future performance. Let's take a closer look. Keytruda: Merck's Biggest Strength Merck boasts more than six blockbuster drugs in its portfolio, with Keytruda being the key top-line driver. Keytruda, approved for several types of cancer, alone accounts for more than 55% of the company's pharmaceutical sales. In the United States, Keytruda is approved for 44 indications spanning 19 tumor types as well as for many of these indications worldwide. The drug has played an instrumental role in driving Merck's steady revenue growth over the past few years. Keytruda sales are gaining from continued strong momentum in metastatic indications and rapid uptake across earlier-stage launches. The company expects the growth to continue till it loses patent exclusivity in 2028. More than 2,800 clinical studies are currently evaluating Keytruda across multiple cancer types and treatment settings. Merck is working on different strategies to drive Keytruda's long-term growth. These include innovative immuno-oncology combinations, including Keytruda with LAG3 and CTLA-4 inhibitors. In partnership with Moderna MRNA, Merck is developing a personalized mRNA therapeutic cancer vaccine called intismeran autogene (V940/mRNA-4157) in combination with Keytruda in pivotal phase III studies for earlier-stage and adjuvant NSCLC and adjuvant melanoma. Merck's subcutaneous formulation of Keytruda, known as Keytruda Qlex, was approved in the United States and EU in 2025 and generated sales of $590 million in the first half of 2026. Keytruda Qlex can offer substantially quicker administration time than the intravenous infusion of Keytruda. Story Continues Merck expects Keytruda to achieve peak sales of $35 billion by 2028. Merck's other oncology drugs, Welireg, AstraZeneca AZN-partnered Lynparza and Eisai-partnered Lenvima, are also contributing to top-line growth. Merck's Animal Health business is also a key contributor to its top-line growth, with sales expected to more than double by the mid-2030s. MRK's Pipeline Progress & Recent M&A Spree Merck's expanding drug pipeline and potential new blockbuster drugs beyond Keytruda look encouraging. Its phase III pipeline has almost tripled since 2021, supported by in-house progress as well as the addition of candidates through M&A deals. Merck expects to launch 20 new drugs by 2030, with many already launched. Its new products, pulmonary arterial hypertension drug Winrevair, cancer drug Welireg and 21-valent pneumococcal conjugate vaccine Capvaxive, have begun to contribute significantly to top-line growth. Some new products approved/launched recently are RSV antibody, Enflonsia (clesrovimab), Idvynso, a once-daily, single-tablet two-drug regimen of doravirine and islatravir, and Lipfendra (enlicitide), an oral PCSK9 inhibitor to help reduce LDL cholesterol in adults with hypercholesterolemia. Some key candidates in late-stage development are sacituzumab tirumotecan or sac-TMT, an anti-TROP2 antibody-drug con", "date_published": "2026-08-11T13:48:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "AZN"], "_sharemaestro": {"country": "Sweden", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "AZN", "name": "AstraZeneca PLC", "sentiment_url": "https://sharemaestro.com/sentiment/9a46cc60-2cd4-4018-a7c4-8318e07d9155/"}]}}, {"id": "source:bf30f98c0e1472cf93cbddab78804d167c1bc8eeeafa21ece51781a2cc7690c3", "url": "https://finance.yahoo.com/technology/articles/prolim-launches-innovation-center-accelerate-133400230.html", "external_url": "https://finance.yahoo.com/technology/articles/prolim-launches-innovation-center-accelerate-133400230.html", "title": "PROLIM Launches New Innovation Center to Accelerate Global Growth", "content_text": "PROLIM Corporation PROLIM Bangalore Inauguration Ribbon Cutting By Siemens ExecutivesPROLIM Bangalore Inauguration Ribbon Cutting By Siemens Executives PROLIM Bangalore OfficePROLIM Bangalore OfficePROLIM Inauguration Bangalore Team Photo BENGALURU, India, Aug. 11, 2026 (GLOBE NEWSWIRE) -- PROLIM, a leading global provider of Product Lifecycle Management (PLM), Digital Engineering, Cloud, and Enterprise AI solutions, proudly announced the inauguration of its Innovation Center in Bengaluru, Karnataka.PROLIM Banglore Office Inauguration Plaque - Siemens Exeutives The center, named the Prof. M. B. Patil Innovation Center, was inaugurated by Siemens executives Tony Hemmelgarn, CEO; Bob Jones, CRO; Bas Kuper, MD, APAC; and Matthew Thomas, CEO and Managing Director of Siemens India. The new facility marks another significant milestone in PROLIM's growth journey and reinforces the company's commitment to innovation, customer success, and the expansion of its global delivery capabilities.PROLIM Innovation Center - Bangalore Designed as a modern and collaborative workspace, the new Innovation Center features a range of advanced technology demonstrations and solutions, including a Product Twin with AR/VR capabilities, a Production Twin featuring Process Simulate integrated with an ABB robot, a Process Twin incorporating executable digital twins and process automation applications, and a Service Twin powered by TeamViewer and robotics. The facility has a seating capacity of more than 400 and will support PROLIM's rapidly growing teams across engineering, cloud, AI, and data analytics. The expansion reflects PROLIM's continued investment in creating an environment that fosters innovation, attracts top talent, and enables customers to solve complex business challenges. Commenting on the inauguration, Prabhu Patil, CEO of PROLIM Global Corporation, said: \"The opening of our state-of-the-art Innovation Center represents an exciting new chapter in PROLIM's journey of innovation and growth. Bengaluru is one of the world's foremost technology and engineering hubs, and this investment strengthens our ability to serve customers, attract exceptional talent, and accelerate digital transformation initiatives across industries.\" Over the years, PROLIM has established itself as a trusted technology partner for organizations across manufacturing, automotive, aerospace, industrial equipment, energy, healthcare, high-tech, and other industries. The company delivers comprehensive Digital Twin and Agentic AI solutions that help organizations transform their products, processes, and operations. \"Our team has always been the driving force behind our success, and this new Innovation Center provides an inspiring environment where innovation, collaboration, and excellence can thrive,\" said Srinath Koppa, Managing Director of PROLIM India. Story Continues PROLIM collaborates with several of the world's leading technology companies, including Siemens, Amazon Web Services (AWS), Microsoft, Mendix, Salesforce, and Snowflake, enabling customers to modernize engineering and business operations, embrace intelligent digital technologies, and accelerate innovation. About PROLIM PROLIM is a global technology and consulting company specializing in Product Lifecycle Management (PLM), Digital Engineering, Cloud, Enterprise Applications, and Digital Transformation solutions. With delivery centers and offices across North America, Europe, and Asia, PROLIM helps organizations transform product development, engineering, manufacturing, and business operations through innovative technology solutions. By combining deep industry expertise with strategic partnerships across leading technology platforms, PROLIM enables customers to accelerate innovation, improve productivity, and achieve measurable business outcomes. Contact: PROLIM Media Team media@prolim.com Photos accompanying this announcement are available at https://www.globenewswire.com/NewsRoom/AttachmentNg/1ca31d4b-0f42-41f3", "date_published": "2026-08-11T13:34:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "ABB"], "_sharemaestro": {"country": "Sweden", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ABB", "name": "ABB Ltd", "sentiment_url": "https://sharemaestro.com/sentiment/e6986ef1-0afe-4acc-97f1-e35f4cb0f117/"}]}}, {"id": "source:560ff950899db574b205aaa6f47db480a16922d63c7a5a2365265f2897e80cc2", "url": "https://finance.yahoo.com/small-business/articles/exclusive-mews-wins-emi-license-133016454.html", "external_url": "https://finance.yahoo.com/small-business/articles/exclusive-mews-wins-emi-license-133016454.html", "title": "Exclusive: Mews wins EMI license, clearing way to hold hotel funds in EEA", "content_text": "Investing.com -- Hospitality software firm Mews has been granted an Electronic Money Institution license by De Nederlandsche Bank, allowing it to hold hotel funds directly rather than routing them through third-party providers, Investing.com has learned. The license was issued to Mews Financial Services B.V., a regulated entity established by the Amsterdam-based company. Mews was last valued at $2.5 billion after raising $300 million in a Series D funding round in January led by EQT Growth, with participation from Atomico, HarbourVest, Kinnevik, Battery Ventures and Tiger Global. The license m", "date_published": "2026-08-11T13:30:16+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "KINV-A", "KINV-B"], "_sharemaestro": {"country": "Sweden", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "KINV-A", "name": "Kinnevik AB", "sentiment_url": "https://sharemaestro.com/sentiment/3537c444-3c23-4049-8b97-c8296f55570a/"}, {"symbol": "KINV-B", "name": "Kinnevik AB", "sentiment_url": "https://sharemaestro.com/sentiment/69b23a96-c1f9-4df6-a8a9-e885762abd4c/"}]}}, {"id": "source:8cec384155e990b0b80560879d2e76c8c9c814d0b10ee735982e9ed4fd14ecda", "url": "https://finance.yahoo.com/energy/articles/energy-transition-abb-partners-levelten-113719756.html", "external_url": "https://finance.yahoo.com/energy/articles/energy-transition-abb-partners-levelten-113719756.html", "title": "Energy Transition Update - ABB Partners With LevelTen To Advance Clean Energy Solutions", "content_text": "ABB has announced a strategic partnership and minority investment in LevelTen Energy, the largest clean energy marketplace worldwide. This partnership aims to enhance ABB's ability to support industrial and commercial customers in securing long-term, affordable clean energy, which is crucial to advancing the energy transition amid a complex grid environment. By integrating LevelTen's market-leading transaction platform with ABB's expertise in electrification and energy management, the collaboration seeks to simplify renewable energy procurement and help businesses navigate the complexities of decarbonization. This move reflects ABB's commitment to working with innovative startups to expand its clean energy solutions and accelerates its efforts to provide comprehensive energy and carbon advisory services. In other market news, Hitachi Energy India was trading firmly up 10.6% and ending trading at \u20b936,050.00. In the meantime, Fluor lagged, down 8.3% to finish the session at $52.25. Fluor's strategic pivot towards high-growth markets could enhance profitability with timely opportunities. Discover more about Fluor's evolving strategy in our detailed narrative. You might find our Market Insights article \"Watt's left in the overcrowded power trade?\" essential reading as it explores looming electricity bottlenecks amid the AI boom, highlighting potential untapped opportunities in the energy transition space\u2014so act now to capitalize on this timely insight. View Comments", "date_published": "2026-08-11T11:37:19+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "ABB"], "_sharemaestro": {"country": "Sweden", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ABB", "name": "ABB Ltd", "sentiment_url": "https://sharemaestro.com/sentiment/e6986ef1-0afe-4acc-97f1-e35f4cb0f117/"}]}}, {"id": "source:fe554c1191a7dbcaa26c115af12013eb71f4be342d20eec97d15a6594f5991b9", "url": "https://finance.yahoo.com/markets/stocks/articles/jim-cramer-recommends-goldman-sachs-054332862.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/jim-cramer-recommends-goldman-sachs-054332862.html", "title": "Jim Cramer Recommends Goldman Sachs and Morgan Stanley to Profit From Accelerating M&A Deals", "content_text": "During Mad Money's August 6 episode, host Jim Cramer highlighted why investors should target elite advisory firms rather than speculating on acquisition targets, as he said: Here's a big theme that right now really only impacts two large companies: pent-up demand for mergers and acquisitions now that the Biden era of overzealous antitrust enforcement has been replaced by the Trump era of almost non-existent antitrust enforcement. Most companies don't believe this moment can last, so they're taking advantage of it to make deals. When the summer's over, I believe we're going to come back to see some blockbusters that are on the order of that rumored AstraZeneca bid for Bristol Myers or Stripe for a real bid for PayPal. I know the targets in these cases may not be interested in merging, but the potential acquirers, oh man, they're all set. They seem very interested, and I think they're willing to pay up. How do you play this merger mania? Not by picking potential targets. That's a sucker game. Instead, you should buy the stocks of the companies that enable these deals. And well, why not Goldman Sachs and Morgan Stanley, both of which have terrific M&A departments? This M&A advisory business is a gold mine. We're talking tremendous earnings per person and therefore, earnings per share.Jim Cramer Backs American Express (AXP) and Capital One (COF) as Consumer Spending Stays Strong Goldman Sachs: Advisory Dominance and Operating Execution Goldman Sachs Group, Inc. (NYSE:GS) continues to demonstrate its position as the premier global M&A franchise, leveraging its institutional relationships to capture dominant market share in cross-border deal structuring. In its second-quarter 2026 financial results, Goldman Sachs delivered total net revenues of $20.34 billion, representing a 39% year-over-year increase and outperforming estimates by $3.94 billion. Net income surged 78% year-over-year to $6.63 billion, driving diluted earnings per share to $20.98, beating estimates by $6.44. The firm achieved an annualized return on average common shareholders' equity of 23.5%. Growth was led by the global banking and markets division, which generated $15.52 billion in net revenues, a 53% year-over-year expansion. Within this segment, investment banking fees jumped 55% year-over-year to $3.40 billion, propelled by accelerating M&A advisory fees, equity underwriting for corporate acquirers, and debt financing packages. During the second-quarter 2026 earnings conference call, Chairman and Chief Executive Officer David Solomon emphasized that dealmaking momentum has accelerated across key coverage sectors, citing expanding advisory pipelines and strong client engagement as corporations act on strategic imperatives. Story Continues Morgan Stanley: Institutional Scale and Advisory Monetization Morgan Stanley (NYSE:MS) represents a complementary pillar in global deal execution, pairing a world-class advisory division with a high-margin wealth management engine that stabilizes firmwide cash flows. In its second-quarter 2026 earnings report, the company posted total net revenues of $21.35 billion, a 27% increase year-over-year. Net income applicable to common shareholders climbed 60% year-over-year to $5.44 billion, with diluted earnings per share of $3.46, exceeding estimates by $0.53. The firm delivered an annualized return on equity of 20.7% and a return on tangible common equity of 26.6%. The firm's institutional securities business segment led top-line expansion, generating $11 billion in net revenues, a 44% year-over-year increase. Investment banking revenues rose 58% year-over-year, driven by higher M&A advisory revenue along with heightened equity underwriting activity. Executive commentary from Morgan Stanley's quarterly earnings discussions highlighted that advisory pipelines continue to build across technology, healthcare, and industrial verticals, supported by corporate sponsors eager to deploy accumulated cash reserves. Smart Money Backs Both In", "date_published": "2026-08-11T05:43:32+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "AZN"], "_sharemaestro": {"country": "Sweden", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "AZN", "name": "AstraZeneca PLC", "sentiment_url": "https://sharemaestro.com/sentiment/9a46cc60-2cd4-4018-a7c4-8318e07d9155/"}]}}, {"id": "source:70170c1ce5e97d7a1068a74666199e82de0d0a02be250a87128adab9d33b40a0", "url": "https://finance.yahoo.com/markets/stocks/articles/rational-ag-ratiy-q2-2026-010402063.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/rational-ag-ratiy-q2-2026-010402063.html", "title": "Rational AG (RATIY) (Q2 2026) Earnings Call Highlights: Record EBIT Margin and Strategic ...", "content_text": "This article first appeared on GuruFocus. Revenue (H1 2026): EUR642 million, up 8% organically and 6% after FX adjustments. Revenue (Q2 2026): EUR324 million, up 4% year-over-year. EBIT (H1 2026): EUR170 million, up 11% year-over-year, with a margin of 26.5% (24.3% excluding tariff refunds). Gross Margin (H1 2026): Improved to 59.8%. Operating Expenses (H1 2026): Increased 5% year-over-year to EUR250 million. iCombi Revenue (H1 2026): EUR562 million, up 5%. iVario Revenue (H1 2026): EUR79 million, up 14%, with North America growing 24%. Germany Revenue (H1 2026): Up 9%. Europe (ex-Germany) Rev", "date_published": "2026-08-11T01:04:02+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "TIETOS"], "_sharemaestro": {"country": "Sweden", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "TIETOS", "name": "Tieto Oyj", "sentiment_url": "https://sharemaestro.com/sentiment/b5f80240-6b95-4861-8916-bb64fa5fe544/"}]}}, {"id": "source:caa3ca6343b4a469f8c41308ea6c793ea1b8dec6c77edd11ad028fa8b67b714e", "url": "https://finance.yahoo.com/markets/stocks/articles/ohb-se-wbo-ohb-q2-010354054.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/ohb-se-wbo-ohb-q2-010354054.html", "title": "OHB SE (WBO:OHB) (Q2 2026) Earnings Call Highlights: Record Backlog and Strategic Growth Amid ...", "content_text": "This article first appeared on GuruFocus. Total Operating Performance: EUR628 million in H1 2026, up from EUR470 million in H1 2024, representing double-digit growth. Adjusted EBITDA: EUR60 million, with a margin of 9.6%, reflecting a 30%+ increase year-on-year. Space Systems Segment Revenue: EUR472 million in total operating performance for H1 2026. Access to Space Segment Growth: Total operating performance grew by more than 30% year-on-year. Digital Segment Backlog: Increased by 70% year-on-year. Cash Flow: Positive free trade working capital cash flow with improved cash conversion, despite one-off cash effects. Net Leverage Ratio: Improved to minus 1.1 following the capital increase. Equity Ratio: More than 40%, indicating strong financial robustness. Employees: Increased by 50% year-on-year to almost 4,100, with increases primarily in operational functions. Backlog: Continued to increase to a record high level, with a pipeline of EUR20 billion in new projects. Guidance: Confirmed for 2026, with total operating performance of about EUR1.4 billion and an adjusted EBITDA margin of 10.5% to 11%. Warning! GuruFocus has detected 5 Warning Signs with WBO:OHB. Is WBO:OHB fairly valued? Test your thesis with our free DCF calculator. Release Date: August 06, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points OHB SE (WBO:OHB) reported double-digit growth in total operating performance, reaching EUR628 million in H1 2026, with adjusted EBITDA up over 30% to EUR60 million. The company's net debt leverage improved significantly to -1.1x following a successful EUR480 million capital increase, strengthening its financial position for future growth. OHB SE (WBO:OHB) has a record-high backlog and a strong pipeline of EUR20 billion in new projects, with key contract negotiations ongoing for ESA, EU, and German defense programs. The company is expanding internationally, with new facilities in the UK and Czech Republic, and has secured significant contracts like PRISMA 2 and the Sova S mission, showcasing its growing prime contractor capabilities. OHB SE (WBO:OHB) confirmed its 2026 guidance of about EUR1.4 billion in total operating performance with a margin of 10.5% to 11%, supported by a strong H1 performance and expected acceleration in H2. Negative Points Order intake in Q2 2026 was lower than expected, with backlog declining sequentially, particularly in Space Systems, due to the lumpy nature of large contracts. The first test flight of Rocket Factory Augsburg (RFA) has been delayed again due to tank issues, requiring the rocket to be removed from the pad for inspection, adding uncertainty to the launch timeline. Access to space segment margins were softer than anticipated in H1 2026, impacted by ramp-up costs and new hires, though expected to improve in H2. The company incurred EUR21 million in transaction-related costs in H1 2026 from the capital increase, and transformation costs are still ongoing, though expected to wind down by next year. Trade working capital saw a large outflow in H1 due to seasonality and project mix, with management only targeting positive free cash flow after working capital by year-end, not guaranteeing it. Story Continues Q & A Highlights Q: What is the outlook for order intake in 2026, and does it include any of the defense opportunities previously discussed?A: Order intake is expected to be back-loaded, with key ESA contracts in final negotiations, including the Sentinel constellation, Clear Space One, and the Upstar mission. On the defense side, large opportunities are not part of 2026 planning, as procurement processes with the German Bundeswehr are expected to materialize starting in 2027 and continue through 2029. Q: Can you provide an update on the Satcom procurement process, including timing and the bid consortium?A: The industrial consortium setup is unchanged, and the procurement process is proceeding as planned by the customer,", "date_published": "2026-08-11T01:03:54+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "BILL"], "_sharemaestro": {"country": "Sweden", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "BILL", "name": "Billerud AB (publ)", "sentiment_url": "https://sharemaestro.com/sentiment/ae46ec7f-2011-4bd8-870f-0d21b34f48f4/"}]}}, {"id": "source:78c6a1bd2ad031fb0a3c1669ca0cca5e3c1df0cd3854841e10d7280098ea7d9b", "url": "https://finance.yahoo.com/healthcare/articles/astrazeneca-azn-reach-80-billion-234403667.html", "external_url": "https://finance.yahoo.com/healthcare/articles/astrazeneca-azn-reach-80-billion-234403667.html", "title": "Can AstraZeneca (AZN) Reach Its $80 Billion Revenue Goal Despite Clinical Setbacks?", "content_text": "It was reported on July 27 that AstraZeneca PLC (NASDAQ:AZN) shares outperformed in European trading after the company reported second-quarter earnings that beat Wall Street expectations and reiterated its full-year 2026 guidance. Core earnings per share (EPS) jumped 18% on a constant exchange rate (FXN) basis year-over-year to $2.63, comfortably ahead of the $2.48 analyst consensus. Total revenue reached $15.38 billion, up 5% at constant exchange rates, driven primarily by sustained momentum in its Oncology and Rare Disease units. Management reconfirmed its full-year 2026 outlook of mid-to-high single-digit revenue growth and low double-digit Core EPS growth, expressing confidence in reaching its $80 billion total revenue target by 2030 despite near-term headwind shocks. The quarter demonstrated strong commercial execution in core growth engines. Oncology revenue rose 16% to $7.33 billion, supported by strong demand for Tagrisso ($1.94 billion), Imfinzi ($1.85 billion), and Enhertu (+31%). Rare Disease contributed $4.9 billion, led by Ultomiris. These gains successfully offset severe pressures in the Cardiovascular, Renal & Metabolism (CVRM) segment, which declined 15% due to the loss of exclusivity (LOE) for Farxiga in the U.S. and ongoing Volume-Based Procurement (VBP) price cuts in China. Meanwhile, pipeline updates presented a mixed picture. On July 27, AZN disclosed that a Phase 3 study evaluating Ultomiris in hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) failed to hit its primary endpoint of event-free survival at week 26 versus placebo. Following the readout, H.C. Wainwright noted that the trial miss represents a \"clear positive\" for competitor Omeros (OMER), removing a major near-term competitive overhang on its drug Yartemlea and driving Omeros shares up 11% in morning trading.Can AstraZeneca (AZN) Reach Its $80 Billion Revenue Goal Despite Clinical Setbacks? BULL CASE AstraZeneca PLC (NASDAQ:AZN)'s core profitability remains elite, with core operating margins expanding to 34% in Q2 despite top-line headwinds from generic entry. High gross and net margins signal durable pricing power across its branded specialty portfolio. This strong profitability generates predictable cash flow to fund heavy R&D investments, commercial rollouts, and growing shareholder returns, including a 3-cent increase in the interim dividend to $1.06 per share, while buffering the company against pricing pressure. The company's expansive late-stage pipeline and high volume of regulatory approvals underpin a multi-year growth trajectory. With 30 major regional approvals since late 2025 and more than 20 high-value trial readouts scheduled over the next 18 months, AZN possesses broad commercial optionality. Continued expansions in oncology (e.g., Enhertu and Imfinzi) and respiratory therapies (such as Breztri and Tezspire) provide direct revenue replacement for legacy products facing patent expiration. Story Continues Finally, robust operating and free cash flows provide capital allocation flexibility. Strong organic cash generation allows management to service debt, maintain strategic M&A optionality, and invest continuously in next-generation platforms like oral GLP-1 agonists without compromising balance sheet stability. BEAR CASE AstraZeneca maintains a sizable absolute debt load, and recent leverage increases reduce financial flexibility if interest rates remain elevated or earnings growth cools. Higher interest payments and refinancing requirements could constrain the capital available for business development, making disciplined debt reduction vital over the coming quarters. Loss-of-exclusivity drags, and regulatory pricing pressures in China remain significant ongoing headwinds. Generics for Farxiga caused global sales of the drug to fall 16% in Q2, while mandatory volume-based procurement (VBP) discounting in China continues to erode baseline CVRM revenues. These structural headwinds force AstraZeneca", "date_published": "2026-08-10T23:44:03+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "AZN"], "_sharemaestro": {"country": "Sweden", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "AZN", "name": "AstraZeneca PLC", "sentiment_url": "https://sharemaestro.com/sentiment/9a46cc60-2cd4-4018-a7c4-8318e07d9155/"}]}}, {"id": "source:36e03b7ae258b399cd78bb7fbb30867e7243c34eb7daf9a750954bd4b19e2d56", "url": "https://finance.yahoo.com/markets/stocks/articles/alrm-asazy-better-value-stock-154002289.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/alrm-asazy-better-value-stock-154002289.html", "title": "ALRM or ASAZY: Which Is the Better Value Stock Right Now?", "content_text": "Investors looking for stocks in the Security and Safety Services sector might want to consider either Alarm.com Holdings (ALRM) or Assa Abloy AB (ASAZY). But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look. There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The proven Zacks Rank emphasizes companies with positive estimate revision trends, and our Style Scores highlight stocks with specific traits. Alarm.com Holdings has a Zacks Rank of #2 (Buy), while Assa Abloy AB has a Zacks Rank of #4 (Sell) right now. Investors should feel comfortable knowing that ALRM likely has seen a stronger improvement to its earnings outlook than ASAZY has recently. But this is just one piece of the puzzle for value investors. Value investors analyze a variety of traditional, tried-and-true metrics to help find companies that they believe are undervalued at their current share price levels. The Value category of the Style Scores system identifies undervalued companies by looking at a number of key metrics. These include the long-favored P/E ratio, P/S ratio, earnings yield, cash flow per share, and a variety of other fundamentals that help us determine a company's fair value. ALRM currently has a forward P/E ratio of 20.44, while ASAZY has a forward P/E of 22.95. We also note that ALRM has a PEG ratio of 1.60. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. ASAZY currently has a PEG ratio of 2.25. Another notable valuation metric for ALRM is its P/B ratio of 3.29. Investors use the P/B ratio to look at a stock's market value versus its book value, which is defined as total assets minus total liabilities. By comparison, ASAZY has a P/B of 3.61. Based on these metrics and many more, ALRM holds a Value grade of B, while ASAZY has a Value grade of C. ALRM sticks out from ASAZY in both our Zacks Rank and Style Scores models, so value investors will likely feel that ALRM is the better option right now. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Alarm.com Holdings, Inc. (ALRM) : Free Stock Analysis Report Assa Abloy AB (ASAZY) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research View Comments", "date_published": "2026-08-10T15:40:02+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "ASSA-B"], "_sharemaestro": {"country": "Sweden", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ASSA-B", "name": "ASSA ABLOY AB (publ)", "sentiment_url": "https://sharemaestro.com/sentiment/2a482587-170a-48d8-872d-84927c180558/"}]}}, {"id": "source:7e14dd60d327e4c0cc93b7a48807c4fb5b2da8c43e6b6d238bbcc359c953ffe2", "url": "https://finance.yahoo.com/healthcare/articles/essity-around-world-july-2026-143000055.html", "external_url": "https://finance.yahoo.com/healthcare/articles/essity-around-world-july-2026-143000055.html", "title": "Essity Around the World - July 2026", "content_text": "NORTHAMPTON, MA / ACCESS Newswire / August 10, 2026 / Originally published on Essity News Center On a regular basis, Essity highlights activities from around the world showcasing how we make a difference in society and in people's lives through hygiene and health. With our products, solutions, and services, we care for a billion people in 150 countries every day. Between April and July 2026, Essity teams around the world advanced initiatives that combined sustainable progress, business development and greater access to hygiene and health, reflecting the company's purpose to improve well-being ", "date_published": "2026-08-10T14:30:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "ESSITY-B", "ESSITY-A"], "_sharemaestro": {"country": "Sweden", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ESSITY-B", "name": "Essity AB (publ)", "sentiment_url": "https://sharemaestro.com/sentiment/f043a2ee-7c47-4868-83f9-64bc536063aa/"}, {"symbol": "ESSITY-A", "name": "Essity AB (publ)", "sentiment_url": "https://sharemaestro.com/sentiment/c03ade82-c718-4f15-92b9-78bea691415c/"}]}}, {"id": "source:e3f8f9e3138170b83471bdcf846b78219ddb47c7cd21ea6ec88f1c1b85d0646c", "url": "https://finance.yahoo.com/energy/articles/international-petroleum-corporation-announces-results-093000449.html", "external_url": "https://finance.yahoo.com/energy/articles/international-petroleum-corporation-announces-results-093000449.html", "title": "International Petroleum Corporation Announces Results of Normal Course Issuer Bid", "content_text": "International Petroleum Corporation International Petroleum Corporation (IPC or the Corporation) (TSX, Nasdaq Stockholm: IPCO) is pleased to announce that IPC repurchased a total of 72,282 IPC common shares (ISIN: CA46016U1084) during the period of August 6 to 7, 2026 under IPC's previously announced normal course issuer bid / share repurchase program (NCIB). IPC's NCIB, announced on December 3, 2025, is being implemented in accordance with the Market Abuse Regulation (EU) No 596/2014 (MAR) and Commission Delegated Regulation (EU) No 2016/1052 (Safe Harbour Regulation) and the applicable rules and policies of the Toronto Stock Exchange (TSX) and Nasdaq Stockholm and applicable Canadian and Swedish securities laws. During the period of August 6 to 7, 2026, IPC repurchased a total of 57,382 IPC common shares on Nasdaq Stockholm. All of these share repurchases were carried out by Pareto Securities AB on behalf of IPC. A summary and detailed breakdown of the transactions conducted on Nasdaq Stockholm during the period of August 6 to 7, 2026 according to article 5.3 of MAR and article 2.3 of the Safe Harbour Regulation is available with this press release on IPC's website: www.international-petroleum.com/news-and-media/press-releases. During the same period, IPC purchased a total of 14,900 IPC common shares on the TSX. All of these share repurchases were carried out by ATB Securities Inc. on behalf of IPC. All common shares repurchased by IPC under the NCIB will be cancelled. As at August 7, 2026, the total number of issued and outstanding IPC common shares is 112,826,752 with voting rights, of which IPC holds 72,282 common shares in treasury. A total of 72,282 IPC common shares have been repurchased under the NCIB through the facilities of the TSX and Nasdaq Stockholm up to August 7, 2026. A maximum of 6,468,077 IPC common shares may be repurchased up to December 4, 2026, or until such earlier date as the NCIB is completed or terminated by IPC. International Petroleum Corp. (IPC) is an international oil and gas exploration and production company with a high quality portfolio of assets located in Canada, Malaysia and France, providing a solid foundation for organic and inorganic growth. IPC is a member of the Lundin Group of Companies. IPC is incorporated in Canada and IPC's shares are listed on the Toronto Stock Exchange (TSX) and the Nasdaq Stockholm exchange under the symbol \"IPCO\". For further information, please contact: Rebecca Gordon SVP Corporate Planning and Investor Relations rebecca.gordon@international-petroleum.com Tel: +41 22 595 10 50 Or Robert Eriksson Media Manager reriksson@rive6.ch Tel: +46 701 11 26 15 Story Continues This information was submitted for publication, through the contact persons set out above, at 11:30 CEST on August 10, 2026. Forward-Looking Statements This press release contains statements and information which constitute \"forward-looking statements\" or \"forward-looking information\" (within the meaning of applicable securities legislation). Such statements and information (together, \"forward-looking statements\") relate to future events, including the Corporation's future performance, business prospects or opportunities. Actual results may differ materially from those expressed or implied by forward-looking statements. The forward-looking statements contained in this press release are expressly qualified by this cautionary statement. Forward-looking statements speak only as of the date of this press release, unless otherwise indicated. IPC does not intend, and does not assume any obligation, to update these forward-looking statements, except as required by applicable laws. All statements other than statements of historical fact may be forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, forecasts, guidance, budgets, objectives, assumptions or future events or performance (often, but not always, using ", "date_published": "2026-08-10T09:30:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "IPCO"], "_sharemaestro": {"country": "Sweden", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "IPCO", "name": "International Petroleum Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/9553895d-cfc1-4e59-900d-ae5a6fbd72ca/"}]}}, {"id": "source:6c887cd7f3a08924d4a7bca2b1881b7de5a9fb960ecdc7b48eb669e463dcc8f3", "url": "https://finance.yahoo.com/markets/stocks/articles/share-buybacks-ericsson-during-period-074300454.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/share-buybacks-ericsson-during-period-074300454.html", "title": "Share buybacks in Ericsson during the period August 3 - August 7, 2026", "content_text": "STOCKHOLM, Aug. 10, 2026 /PRNewswire/ -- During the period August 3 - August 7, 2026, Telefonaktiebolaget LM Ericsson (publ) (\"Ericsson\") (LEI code 549300W9JLPW15XIFM52) repurchased own Class B shares (ISIN: SE0000108656) as follows: Date Aggregated daily volume (number of shares) Weighted average share price per day (SEK) Total daily transaction value (SEK) 03/08/2026 500,000 95.7186 47,859,300.00 04/08/2026 500,000 97.6833 48,841,650.00 05/08/2026 1,000,000 97.4855 97,485,500.00 06/08/2026 1,000,000 96.6100 96,610,000.00 07/08/2026 1,000,000 96.6658 96,665,800.00 Total 4,000,000 96.8656 387,", "date_published": "2026-08-10T07:43:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Capital return", "ERIC-A", "ERIC-B"], "_sharemaestro": {"country": "Sweden", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ERIC-A", "name": "Telefonaktiebolaget LM Ericsson (publ)", "sentiment_url": "https://sharemaestro.com/sentiment/55d58cf9-6ad7-46ac-b3d2-b3ac3eb4d992/"}, {"symbol": "ERIC-B", "name": "Telefonaktiebolaget LM Ericsson (publ)", "sentiment_url": "https://sharemaestro.com/sentiment/ef94dea1-4ffa-4fd3-b67c-cfec302a2322/"}]}}, {"id": "source:1ccb6d99c5cf0b92518425bf43eb9ae2dd5e9d8799ba160e8c558c14d02bf601", "url": "https://finance.yahoo.com/healthcare/articles/sobi-enters-strategic-partnership-innate-063600544.html", "external_url": "https://finance.yahoo.com/healthcare/articles/sobi-enters-strategic-partnership-innate-063600544.html", "title": "Sobi enters strategic partnership with Innate Pharma to license lacutamab in T-cell lymphoma", "content_text": "STOCKHOLM, Aug. 10, 2026 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi\u00ae) and Innate Pharma SA (Euronext Paris: IPH) (NASDAQ: IPHA) (\"Innate\" or the \"Company\") today announced that they have entered a strategic partnership to enable initiation of the TELLOMAK-3 confirmatory Phase 3 study in cutaneous T cell lymphoma (CTCL), a key step toward filing for accelerated approval of lacutamab in S\u00e9zary syndrome, a subtype of CTCL. Under the agreement, Innate will conduct the TELLOMAK-3 Phase 3 confirmatory trial in cutaneous T-cell lymphoma, supporting a planned accelerated approval filing ", "date_published": "2026-08-10T06:36:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Deals and strategy", "SOBI"], "_sharemaestro": {"country": "Sweden", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "SOBI", "name": "Swedish Orphan Biovitrum AB (publ)", "sentiment_url": "https://sharemaestro.com/sentiment/24740157-b105-49f6-b0a8-742fd62565fa/"}]}}, {"id": "source:52533b842c5b885c192daa27b72be46f1a97a31743655ce4d6e8dbb8882309f5", "url": "https://finance.yahoo.com/markets/stocks/articles/share-buy-back-programme-transactions-062600825.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/share-buy-back-programme-transactions-062600825.html", "title": "Share Buy-back Programme \u2013 Transactions Week 32", "content_text": "Gabriel Holding A/S On 12 May 2026, Gabriel Holding A/S initiated a share buy-back programme. The buy-back runs from 12 May 2026 up to and including 16 March 2027. During this period, Gabriel Holding A/S may repurchase up to 94,500 shares corresponding to 5% of the share capital. Gabriel Holding A/S held 55,109 treasury shares at the start of the share buyback programme. The buy-back is executed in accordance with Article 5 of Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052, also referred to as", "date_published": "2026-08-10T06:26:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Capital return", "BURE", "NCC-A", "NCC-B"], "_sharemaestro": {"country": "Sweden", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "BURE", "name": "Bure Equity AB (publ)", "sentiment_url": "https://sharemaestro.com/sentiment/02ca7714-1e2d-44b3-a4be-082a42c9442f/"}, {"symbol": "NCC-A", "name": "NCC AB (publ)", "sentiment_url": "https://sharemaestro.com/sentiment/0cfb6c1e-fd9f-48cc-a111-490dcfa36b3f/"}, {"symbol": "NCC-B", "name": "NCC AB (publ)", "sentiment_url": "https://sharemaestro.com/sentiment/cddef924-1cd5-4494-ae07-d8759816a49a/"}]}}, {"id": "source:3133bc64366d64e301cce95e83d920f03f06953b86a05222f07b6b0fe7d1a2db", "url": "https://finance.yahoo.com/markets/stocks/articles/yubico-ab-yubcf-q2-2026-030028244.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/yubico-ab-yubcf-q2-2026-030028244.html", "title": "Yubico AB (YUBCF) (Q2 2026) Earnings Call Highlights: 12% Organic Growth and 80% Gross Margin ...", "content_text": "This article first appeared on GuruFocus. Net Sales Growth: 12% organic development in Q2 2026. Order Bookings: Organic development of -5%. EBIT: SEK 79 million, with a margin of 14.4%, up 12 percentage points year-over-year. Gross Profit Margin: 80%, at the higher end of the guided range. Small and Mid-Size Bookings: Grew 18%. Perpetual Bookings: Grew 7%, primarily driven by deals below SEK 3 million. YubiKey as a Service: Represented 24% of total bookings. Gross Retention Rate: 98%. Net Retention Rate: 107%. Cash Flow from Operating Activities: Strong, driven by high profitability, before wo", "date_published": "2026-08-09T03:00:28+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "YUBICO"], "_sharemaestro": {"country": "Sweden", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "YUBICO", "name": "Yubico AB", "sentiment_url": "https://sharemaestro.com/sentiment/dee9e9ce-e99f-4d11-b51e-5653caa363fc/"}]}}, {"id": "source:6c5944141456f01217fe23b092d2db76ce682e05e0ca2c7ffbcfb4f2cb436086", "url": "https://finance.yahoo.com/markets/stocks/articles/lundin-gold-inc-lugdf-q2-010256153.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/lundin-gold-inc-lugdf-q2-010256153.html", "title": "Lundin Gold Inc (LUGDF) (Q2 2026) Earnings Call Highlights: Strong Production and Record ...", "content_text": "This article first appeared on GuruFocus. Release Date: August 07, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Lundin Gold Inc (LUGDF) delivered strong Q2 2026 operational performance with production of approximately 119,000 ounces, bringing year-to-date output to 239,000 ounces and reaffirming full-year guidance of 475,000-525,000 ounces. The company generated robust free cash flow of $96 million in Q2, even after making annual tax and profit-sharing payments of $221 million, and ended the first half with a strong c", "date_published": "2026-08-09T01:02:56+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "LUG"], "_sharemaestro": {"country": "Sweden", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "LUG", "name": "Lundin Gold Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/e3b70544-d965-4576-bcb3-83d18305d29e/"}]}}, {"id": "source:31d36c07c78985ca23ce8479da2fd2e349bbc25f17b90431661cfb44df893e30", "url": "https://finance.yahoo.com/markets/stocks/articles/does-red-cat-holdings-rcat-171426830.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/does-red-cat-holdings-rcat-171426830.html", "title": "What Does Red Cat Holdings (RCAT) Need To Prove After Its Latest Advances?", "content_text": "Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Red Cat Holdings (NasdaqCM: RCAT) reports significant revenue and margin growth alongside progress in key defense and autonomy programs. The company advances to the final stages of a major U.S. military drone procurement process under the Drone Dominance program. Red Cat completes the acquisition of Quaze Technologies, adding new capabilities in autonomous platform technology. Subsidiary Blue Ops reaches a product integration milestone with Volvo Penta's marine propulsion system in the Variant 7 uncrewed surface vessel. Readers looking for more ways to play the rise of autonomous systems and defense-focused automation can explore related stocks through 36 robotics and automation stocksNasdaqCM:RCAT Earnings & Revenue Growth as at Aug 2026 Red Cat Holdings now sits at the intersection of defense, autonomy and uncrewed maritime systems, which helps explain why the stock's move has been sharp at times. The share price is US$9.21, with the stock up 22.3% over the past week and showing a very large gain over three years, even though it has declined 1.3% over the past year. We've flagged 5 risks for Red Cat Holdings. See which could impact your investment. How did Red Cat Holdings' results actually change this quarter? Red Cat Holdings reported Q2 2026 sales of US$20.19 million compared with US$3.22 million a year earlier, which is a very large year on year increase. Management also highlighted higher gross margins versus both Q2 2025 and Q1 2026. At the same time, the company reported a larger net loss of US$35.26 million, compared with a loss of US$13.28 million a year ago. For the first half, sales were US$35.66 million compared with US$4.85 million a year earlier, while the net loss widened to US$61.81 million from US$36.4 million. Investors are seeing a business that is scaling revenue but still spending heavily. What does this mean for the Red Cat Holdings Narrative on defense autonomy? The core Narrative now ties Teal Drones in the Drone Dominance program, Quaze Technologies' wireless power transfer and Blue Ops' Variant 7 uncrewed surface vessel into one multi domain autonomy story. Advancing to Gauntlet II in a major U.S. military drone procurement process, plus Quaze's technology for longer duration missions, points to a broader platform approach across air, sea and potentially other domains. The Volvo Penta integration into the V7 gives defense and homeland security customers access to a known propulsion supplier with a global service network, which can help operational uptime. The trade off for investors is that building this wider platform is coinciding with higher losses and shareholder dilution. Story Continues What should investors watch next from Red Cat Holdings? A key near term signpost is the outcome of the Drone Dominance program after Gauntlet II, since this is a defined procurement process that could influence Teal Drones' order pipeline. On the financial side, investors can track whether quarterly sales stay above the Q2 2026 level of US$20.19 million while losses begin to narrow from the current US$35.26 million quarterly net loss and US$61.81 million first half net loss. Progress on Blue Ops' V7 full rate production and any disclosed order quantities will also show how quickly the uncrewed surface portfolio converts from product milestones to recurring contracts. For the full picture including more risks and rewards, check out the complete Red Cat Holdings analysis. Alternatively, you can check out the community page for Red Cat Holdings to see how other investors believe this latest news will impact the company's narrative. Stay updated on the most important news stories for Red Cat Holdings by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Red Cat Holdings. This article by Simply Wall St is general in nat", "date_published": "2026-08-08T17:14:26+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "VOLV-A", "VOLV-B"], "_sharemaestro": {"country": "Sweden", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "VOLV-A", "name": "AB Volvo (publ)", "sentiment_url": "https://sharemaestro.com/sentiment/fe8d0ecb-cf08-4cc7-bbe9-922c031ed18e/"}, {"symbol": "VOLV-B", "name": "AB Volvo (publ)", "sentiment_url": "https://sharemaestro.com/sentiment/f1d39f99-f2ad-497c-a0ad-50650ec0e904/"}]}}, {"id": "source:2ce674b337483eaa8cdb7407eb2350e4630b953f63dafef1c2bbd3a4558cba28", "url": "https://finance.yahoo.com/healthcare/articles/astrazeneca-lse-azn-signs-two-151237153.html", "external_url": "https://finance.yahoo.com/healthcare/articles/astrazeneca-lse-azn-signs-two-151237153.html", "title": "AstraZeneca (LSE:AZN) Signs Two Cancer Diagnostics Deals To Widen Patient Access", "content_text": "Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. SOPHiA GENETICS and AstraZeneca (LSE:AZN) have entered a global partnership to develop and launch two decentralized companion diagnostics in precision oncology. The multi-year collaboration focuses on clinical trial assays that support development and commercialization of AstraZeneca's oncology therapies. The partners aim to expand access to personalized cancer treatments by enabling decentralized testing across a wider range of clinical settings. For readers tracking how data driven tools are changing drug discovery and cancer care, it is worth looking more broadly at the companies building these capabilities through 6 healthcare AI stocksLSE:AZN Earnings & Revenue Growth as at Aug 2026 AstraZeneca sits among the large global pharmaceutical companies with a strong focus on oncology, so investors often watch how new partnerships align with that core specialty. The stock trades at \u00a3118.96 and has been volatile recently, with the share price down over the past week and month, yet still showing gains over the past year and over multi year periods. Beyond the headline: 2 risks and 4 things going right for AstraZeneca that every investor should see. How does this SOPHiA GENETICS deal actually change things for AstraZeneca? The agreement gives AstraZeneca access to SOPHiA GENETICS's decentralized Solid Tumor and Hematological Oncology diagnostic platforms for use as companion diagnostics. That links AstraZeneca's oncology drugs directly to assays that can run in a wider range of hospitals, not only in central labs. For AstraZeneca, this can support uptake of existing and future cancer therapies where treatment decisions rely on accurate biomarker testing, and it ties real world data generation more tightly to its portfolio. What does this mean for the AstraZeneca oncology Narrative? The Narrative around AstraZeneca centers on oncology approvals, late stage assets such as Datroway and Sone Ve, and use of data and technology to support precision medicine. Partnering with SOPHiA GENETICS fits that story by building the diagnostic side needed for targeted drugs to reach the right patients. It also sits alongside other alliances like Pathos AI, reinforcing a pattern of AstraZeneca using external platforms to support its R&D and commercial ambitions rather than relying only on internal tools. What should investors watch next from this diagnostics partnership? The key marker will be when the first SOPHiA based companion diagnostic linked to an AstraZeneca therapy is validated and cleared by regulators in a major market such as the US or EU. Concrete updates on regulatory submissions, specific cancer indications covered, and uptake of decentralized assays in clinical trial settings will show whether this collaboration is translating into broader real world use of AstraZeneca's oncology drugs. Story Continues For the full picture including more risks and rewards, check out the complete AstraZeneca analysis. Alternatively, you can check out the community page for AstraZeneca to see how other investors believe this latest news will impact the company's narrative. Do you think there's more to the story for AstraZeneca? Head over to our Community to see what others are saying! This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include AZN.L. Have feedback on this ", "date_published": "2026-08-08T15:12:37+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "AZN"], "_sharemaestro": {"country": "Sweden", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "AZN", "name": "AstraZeneca PLC", "sentiment_url": "https://sharemaestro.com/sentiment/9a46cc60-2cd4-4018-a7c4-8318e07d9155/"}]}}]}